{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T21:22:27Z","timestamp":1788556947805,"version":"build-2803163510"},"reference-count":499,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02780-8","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T23:02:20Z","timestamp":1782860540000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Advances and prospects in cell therapy for cancer: explorations from T cells to stem cells"],"prefix":"10.1038","volume":"11","author":[{"given":"Guisha","family":"Zi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiansheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runxuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengdou","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6435-9368","authenticated-orcid":false,"given":"Jia","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8636-0493","authenticated-orcid":false,"given":"Xiaoping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"2780_CR1","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel, R. L. et al. Cancer statistics, 2025. CA Cancer J. Clin. 75, 10\u201345 (2025).","journal-title":"CA Cancer J. Clin."},{"key":"2780_CR2","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"2780_CR3","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/S0140-6736(25)01635-6","volume":"406","author":"GBD 2023 Breast Cancer Collaborators","year":"2025","unstructured":"GBD 2023 Breast Cancer Collaborators The global, regional, and national burden of cancer, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023. Lancet 406, 1565\u20131586 (2025).","journal-title":"Lancet"},{"key":"2780_CR4","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S0140-6736(21)00001-5","volume":"397","author":"GlobalSurg Collaborative and National Institute for Health Research Global Health Research Unit on Global Surgery","year":"2021","unstructured":"GlobalSurg Collaborative and National Institute for Health Research Global Health Research Unit on Global Surgery Global variation in postoperative mortality and complications after cancer surgery: a multicentre, prospective cohort study in 82 countries. Lancet 397, 387\u2013397 (2021).","journal-title":"Lancet"},{"key":"2780_CR5","first-page":"105","volume":"70","author":"J Cortes","year":"2020","unstructured":"Cortes, J. et al. Enhancing global access to cancer medicines. CA Cancer J. Clin. 70, 105\u2013124 (2020).","journal-title":"CA Cancer J. Clin."},{"key":"2780_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02489-2","volume":"24","author":"B Chen","year":"2025","unstructured":"Chen, B. et al. Antibody-drug conjugates in cancer therapy: current landscape, challenges, and future directions. Mol. Cancer 24, 279 (2025).","journal-title":"Mol. Cancer"},{"key":"2780_CR7","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","volume":"18","author":"R Wang","year":"2025","unstructured":"Wang, R. et al. Antibody-Drug Conjugates (ADCs): current and future biopharmaceuticals. J. Hematol. Oncol. 18, 51 (2025).","journal-title":"J. Hematol. Oncol."},{"key":"2780_CR8","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/s44222-023-00030-y","volume":"1","author":"J Deckers","year":"2023","unstructured":"Deckers, J. et al. Engineering cytokine therapeutics. Nat. Rev. Bioeng. 1, 286\u2013303 (2023).","journal-title":"Nat. Rev. Bioeng."},{"key":"2780_CR9","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41577-023-00982-7","volume":"24","author":"A Fenis","year":"2024","unstructured":"Fenis, A. et al. New immune cell engagers for cancer immunotherapy. Nat. Rev. Immunol. 24, 471\u2013486 (2024).","journal-title":"Nat. Rev. Immunol."},{"key":"2780_CR10","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/s41573-022-00476-6","volume":"21","author":"CJ Bashor","year":"2022","unstructured":"Bashor, C. J. et al. Engineering the next generation of cell-based therapeutics. Nat. Rev. Drug Discov. 21, 655\u2013675 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2780_CR11","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ando.2010.01.003","volume":"71","author":"JJ Lefr\u00e8re","year":"2010","unstructured":"Lefr\u00e8re, J. J. & Berche, P. [Doctor Brown-Sequard\u2019s therapy]. Ann. Endocrinol. 71, 69\u201375 (2010).","journal-title":"Ann. Endocrinol."},{"key":"2780_CR12","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1172\/JCI103949","volume":"38","author":"ED Thomas","year":"1959","unstructured":"Thomas, E. D. et al. Supralethal whole body irradiation and isologous marrow transplantation in man. J. Clin. Invest. 38, 1709\u20131716 (1959).","journal-title":"J. Clin. Invest."},{"key":"2780_CR13","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1056\/NEJM198512053132327","volume":"313","author":"SA Rosenberg","year":"1985","unstructured":"Rosenberg, S. A. et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med. 313, 1485\u20131492 (1985).","journal-title":"N. Engl. J. Med."},{"key":"2780_CR14","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1073\/pnas.90.2.720","volume":"90","author":"Z Eshhar","year":"1993","unstructured":"Eshhar, Z., Waks, T., Gross, G. & Schindler, D. G. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc. Natl. Acad. Sci. USA 90, 720\u2013724 (1993).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2780_CR15","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439\u2013448 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2780_CR16","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","volume":"10","author":"I Zugasti","year":"2025","unstructured":"Zugasti, I. et al. CAR-T cell therapy for cancer: current challenges and future directions. Signal Transduct. Target. Ther. 10, 210 (2025).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2780_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-020-00237-w","volume":"8","author":"Q Liao","year":"2020","unstructured":"Liao, Q. et al. PD-L1 chimeric costimulatory receptor improves the efficacy of CAR-T cells for PD-L1-positive solid tumors and reduces toxicity in vivo. Biomark. Res. 8, 57 (2020).","journal-title":"Biomark. Res."},{"key":"2780_CR18","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1038\/s41565-021-00982-5","volume":"16","author":"NT Nguyen","year":"2021","unstructured":"Nguyen, N. T. et al. Nano-optogenetic engineering of CAR T cells for precision immunotherapy with enhanced safety. Nat. Nanotechnol. 16, 1424\u20131434 (2021).","journal-title":"Nat. Nanotechnol."},{"key":"2780_CR19","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/d41573-025-00180-1","volume":"24","author":"F Benthani","year":"2025","unstructured":"Benthani, F., Upadhaya, S. & Zhou, A. Cancer cell therapies: global clinical trial trends and emerging directions. Nat. Rev. Drug Discov. 24, 898\u2013899 (2025).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2780_CR20","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/nri2635","volume":"9","author":"CH June","year":"2009","unstructured":"June, C. H., Blazar, B. R. & Riley, J. L. Engineering lymphocyte subsets: tools, trials and tribulations. Nat. Rev. Immunol. 9, 704\u2013716 (2009).","journal-title":"Nat. Rev. Immunol."},{"key":"2780_CR21","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13045-025-01737-8","volume":"18","author":"N Jiang","year":"2025","unstructured":"Jiang, N. et al. Recent advances in universal chimeric antigen receptor T cell therapy. J. Hematol. Oncol. 18, 82 (2025).","journal-title":"J. Hematol. Oncol."},{"key":"2780_CR22","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June, C. H. & Sadelain, M. Chimeric antigen receptor therapy. N. Engl. J. Med. 379, 64\u201373 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2780_CR23","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nature22395","volume":"545","author":"M Sadelain","year":"2017","unstructured":"Sadelain, M., Rivi\u00e8re, I. & Riddell, S. Therapeutic T cell engineering. Nature 545, 423\u2013431 (2017).","journal-title":"Nature"},{"key":"2780_CR24","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/j.ccell.2024.07.002","volume":"42","author":"U Uslu","year":"2024","unstructured":"Uslu, U., Castelli, S. & June, C. H. CAR T cell combination therapies to treat cancer. Cancer Cell 42, 1319\u20131325 (2024).","journal-title":"Cancer Cell"},{"key":"2780_CR25","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1182\/blood-2013-11-492231","volume":"123","author":"MV Maus","year":"2014","unstructured":"Maus, M. V., Grupp, S. A., Porter, D. L. & June, C. H. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 123, 2625\u20132635 (2014).","journal-title":"Blood"},{"key":"2780_CR26","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.75660","volume":"11","author":"A Elazar","year":"2022","unstructured":"Elazar, A. et al. De novo-designed transmembrane domains tune engineered receptor functions. eLife 11, e75660 (2022).","journal-title":"eLife"},{"key":"2780_CR27","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1146\/annurev-immunol-042718-041407","volume":"37","author":"S Guedan","year":"2019","unstructured":"Guedan, S., Ruella, M. & June, C. H. Emerging cellular therapies for cancer. Annu. Rev. Immunol. 37, 145\u2013171 (2019).","journal-title":"Annu. Rev. Immunol."},{"key":"2780_CR28","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41571-021-00530-z","volume":"18","author":"KM Cappell","year":"2021","unstructured":"Cappell, K. M. & Kochenderfer, J. N. A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains. Nat. Rev. Clin. Oncol. 18, 715\u2013727 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2780_CR29","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1016\/j.ymthe.2025.03.005","volume":"33","author":"KK Patel","year":"2025","unstructured":"Patel, K. K. et al. From concept to cure: the evolution of CAR-T cell therapy. Mol. Ther. 33, 2123\u20132140 (2025).","journal-title":"Mol. Ther."},{"key":"2780_CR30","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/0006-291X(87)90502-X","volume":"149","author":"Y Kuwana","year":"1987","unstructured":"Kuwana, Y. et al. Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions. Biochem. Biophys. Res. Commun. 149, 960\u2013968 (1987).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2780_CR31","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/0092-8674(91)90314-O","volume":"64","author":"BA Irving","year":"1991","unstructured":"Irving, B. A. & Weiss, A. The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways. Cell 64, 891\u2013901 (1991).","journal-title":"Cell"},{"key":"2780_CR32","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrc971","volume":"3","author":"M Sadelain","year":"2003","unstructured":"Sadelain, M., Rivi\u00e8re, I. & Brentjens, R. Targeting tumours with genetically enhanced T lymphocytes. Nat. Rev. Cancer 3, 35\u201345 (2003).","journal-title":"Nat. Rev. Cancer"},{"key":"2780_CR33","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","volume":"3","author":"M Sadelain","year":"2013","unstructured":"Sadelain, M., Brentjens, R. & Rivi\u00e8re, I. The basic principles of chimeric antigen receptor design. Cancer Discov. 3, 388\u2013398 (2013).","journal-title":"Cancer Discov."},{"key":"2780_CR34","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nri3405","volume":"13","author":"L Chen","year":"2013","unstructured":"Chen, L. & Flies, D. B. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat. Rev. Immunol. 13, 227\u2013242 (2013).","journal-title":"Nat. Rev. Immunol."},{"key":"2780_CR35","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-CELL Lymphoma. N. Engl. J. Med. 377, 2531\u20132544 (2017).","journal-title":"N. Engl. J. Med."},{"key":"2780_CR36","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"DL Porter","year":"2011","unstructured":"Porter, D. L. et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725\u2013733 (2011).","journal-title":"N. Engl. J. Med."},{"key":"2780_CR37","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1038\/s41375-019-0417-9","volume":"33","author":"MR Collinson-Pautz","year":"2019","unstructured":"Collinson-Pautz, M. R. et al. Constitutively active MyD88\/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies. Leukemia 33, 2195\u20132207 (2019).","journal-title":"Leukemia"},{"key":"2780_CR38","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/d41573-023-00140-7","volume":"22","author":"M Verma","year":"2023","unstructured":"Verma, M. et al. The next-generation CAR-T therapy landscape. Nat. Rev. Drug Discov. 22, 776\u2013777 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2780_CR39","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ccell.2020.07.005","volume":"38","author":"M Hong","year":"2020","unstructured":"Hong, M., Clubb, J. D. & Chen, Y. Y. Engineering CAR-T cells for next-generation cancer therapy. Cancer Cell 38, 473\u2013488 (2020).","journal-title":"Cancer Cell"},{"key":"2780_CR40","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/nm.4478","volume":"24","author":"Y Kagoya","year":"2018","unstructured":"Kagoya, Y. et al. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects. Nat. Med. 24, 352\u2013359 (2018).","journal-title":"Nat. Med."},{"key":"2780_CR41","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell, K. M. & Kochenderfer, J. N. Long-term outcomes following CAR T cell therapy: what we know so far. Nat. Rev. Clin. Oncol. 20, 359\u2013371 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2780_CR42","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","volume":"602","author":"JJ Melenhorst","year":"2022","unstructured":"Melenhorst, J. J. et al. Decade-long leukaemia remissions with persistence of CD4+ CAR T cells. Nature 602, 503\u2013509 (2022).","journal-title":"Nature"},{"key":"2780_CR43","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13045-025-01701-6","volume":"18","author":"H Qin","year":"2025","unstructured":"Qin, H. et al. Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects. J. Hematol. Oncol. 18, 62 (2025).","journal-title":"J. Hematol. Oncol."},{"key":"2780_CR44","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/d41573-024-00094-4","volume":"23","author":"AR Saez-Iba\u00f1ez","year":"2024","unstructured":"Saez-Iba\u00f1ez, A. R. et al. The changing landscape of cancer cell therapies: clinical trials and real-world data. Nat. Rev. Drug Discov. 23, 736\u2013737 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2780_CR45","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1056\/NEJMp1711886","volume":"377","author":"L Rosenbaum","year":"2017","unstructured":"Rosenbaum, L. Tragedy, perseverance, and chance - the story of CAR-T therapy. N. Engl. J. Med. 377, 1313\u20131315 (2017).","journal-title":"N. Engl. J. Med."},{"key":"2780_CR46","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S0140-6736(24)00746-3","volume":"404","author":"MJ Frank","year":"2024","unstructured":"Frank, M. J. et al. CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study. Lancet 404, 353\u2013363 (2024).","journal-title":"Lancet"},{"key":"2780_CR47","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1200\/JCO.24.00321","volume":"43","author":"GW Roloff","year":"2025","unstructured":"Roloff, G. W. et al. Outcomes after brexucabtagene autoleucel administered as a standard therapy for adults with relapsed\/refractory B-Cell ALL. J. Clin. Oncol. 43, 558\u2013566 (2025).","journal-title":"J. Clin. Oncol."},{"key":"2780_CR48","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507\u20131517 (2014).","journal-title":"N. Engl. J. Med."},{"key":"2780_CR49","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1200\/JCO.22.01214","volume":"41","author":"T Wang","year":"2023","unstructured":"Wang, T. et al. Coadministration of CD19- and CD22-directed chimeric antigen receptor T-cell therapy in childhood B-cell acute lymphoblastic leukemia: a single-arm, multicenter, phase II trial. J. Clin. Oncol. 41, 1670\u20131683 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2780_CR50","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang, M. et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med. 382, 1331\u20131342 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2780_CR51","doi-asserted-by":"publisher","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","volume":"4","author":"MC Pasquini","year":"2020","unstructured":"Pasquini, M. C. et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 4, 5414\u20135424 (2020).","journal-title":"Blood Adv."},{"key":"2780_CR52","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke, F. L. et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N. Engl. J. Med. 386, 640\u2013654 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2780_CR53","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","volume":"391","author":"C Roddie","year":"2024","unstructured":"Roddie, C. et al. Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia. N. Engl. J. Med. 391, 2219\u20132230 (2024).","journal-title":"N. Engl. J. Med."},{"key":"2780_CR54","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384, 705\u2013716 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2780_CR55","doi-asserted-by":"publisher","first-page":"8009","DOI":"10.1200\/JCO.2023.41.16_suppl.8009","volume":"41","author":"Y Lin","year":"2023","unstructured":"Lin, Y. et al. CARTITUDE-1 final results: phase 1b\/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed\/refractory multiple myeloma. J. Clin. Oncol. 41, 8009 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2780_CR56","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1200\/JCO-25-00760","volume":"43","author":"S Jagannath","year":"2025","unstructured":"Jagannath, S. et al. Long-term (\u22655-year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed\/refractory multiple myeloma. J. Clin. Oncol. 43, 2766\u20132771 (2025).","journal-title":"J. Clin. Oncol."},{"key":"2780_CR57","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1182\/blood-2023-178933","volume":"142","author":"P Rodr\u00edguez Otero","year":"2023","unstructured":"Rodr\u00edguez Otero, P. et al. Idecabtagene vicleucel (ide-cel) versus standard (std) regimens in patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): updated analysis from KarMMa-3. Blood 142, 1028 (2023).","journal-title":"Blood"},{"key":"2780_CR58","doi-asserted-by":"publisher","first-page":"7539","DOI":"10.1200\/JCO.2025.43.16_suppl.7539","volume":"43","author":"S Sidana","year":"2025","unstructured":"Sidana, S. et al. Ciltacabtagene autoleucel (cilta-cel) vs standard of care (SOC) in patients (pts) with relapsed\/refractory multiple myeloma (MM): CARTITUDE-4 survival subgroup analyses. J. Clin. Oncol. 43, 7539 (2025).","journal-title":"J. Clin. Oncol."},{"key":"2780_CR59","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1182\/blood.2021015020","volume":"140","author":"A Freiwan","year":"2022","unstructured":"Freiwan, A. et al. Engineering naturally occurring CD7- T cells for the immunotherapy of hematological malignancies. Blood 140, 2684\u20132696 (2022).","journal-title":"Blood"},{"key":"2780_CR60","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1016\/S2352-3026(22)00378-7","volume":"10","author":"DA Sallman","year":"2023","unstructured":"Sallman, D. A. et al. CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial. Lancet Haematol. 10, e191\u2013e202 (2023).","journal-title":"Lancet Haematol."},{"key":"2780_CR61","doi-asserted-by":"publisher","first-page":"3145","DOI":"10.1182\/blood.2020009759","volume":"137","author":"M Wermke","year":"2021","unstructured":"Wermke, M. et al. Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed\/refractory AML. Blood 137, 3145\u20133148 (2021).","journal-title":"Blood"},{"key":"2780_CR62","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1182\/blood.2020009192","volume":"138","author":"H Jetani","year":"2021","unstructured":"Jetani, H. et al. Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia. Blood 138, 1830\u20131842 (2021).","journal-title":"Blood"},{"key":"2780_CR63","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1200\/JCO.23.02314","volume":"42","author":"C Qi","year":"2024","unstructured":"Qi, C. et al. Safety and efficacy of CT041 in patients with refractory metastatic pancreatic cancer: a pooled analysis of two early-phase trials. J. Clin. Oncol. 42, 2565\u20132577 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2780_CR64","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/s41591-024-02875-1","volume":"30","author":"CE Brown","year":"2024","unstructured":"Brown, C. E. et al. Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial. Nat. Med. 30, 1001\u20131012 (2024).","journal-title":"Nat. Med."},{"key":"2780_CR65","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41586-024-08171-9","volume":"637","author":"M Monje","year":"2025","unstructured":"Monje, M. et al. Intravenous and intracranial GD2-CAR T cells for H3K27M(+) diffuse midline gliomas. Nature 637, 708\u2013715 (2025).","journal-title":"Nature"},{"key":"2780_CR66","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1016\/S0140-6736(25)00860-8","volume":"405","author":"C Qi","year":"2025","unstructured":"Qi, C. et al. Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician\u2019s choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial. Lancet 405, 2049\u20132060 (2025).","journal-title":"Lancet"},{"key":"2780_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-65148-6","volume":"16","author":"EJ Carstens","year":"2025","unstructured":"Carstens, E. J. et al. Modeling and addressing on-target\/off-tumor toxicity of claudin 18.2 targeted immunotherapies. Nat. Commun. 16, 9651 (2025).","journal-title":"Nat. Commun."},{"key":"2780_CR68","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1146\/annurev-med-070623-045906","volume":"76","author":"PD Zang","year":"2025","unstructured":"Zang, P. D., Angeles, A. & Pal, S. K. CD70: an emerging anticancer target in renal cell carcinoma and beyond. Annu. Rev. Med. 76, 257\u2013266 (2025).","journal-title":"Annu. Rev. Med."},{"key":"2780_CR69","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1158\/2159-8290.CD-24-0102","volume":"14","author":"SK Pal","year":"2024","unstructured":"Pal, S. K. et al. CD70-targeted allogeneic CAR T-cell therapy for advanced clear cell renal cell carcinoma. Cancer Discov. 14, 1176\u20131189 (2024).","journal-title":"Cancer Discov."},{"key":"2780_CR70","doi-asserted-by":"publisher","first-page":"4508","DOI":"10.1200\/JCO.2025.43.16_suppl.4508","volume":"43","author":"SA Srour","year":"2025","unstructured":"Srour, S. A. et al. ALLO-316 in advanced clear cell renal cell carcinoma (ccRCC): Updated results from the phase 1 TRAVERSE study. J. Clin. Oncol. 43, 4508 (2025).","journal-title":"J. Clin. Oncol."},{"key":"2780_CR71","doi-asserted-by":"publisher","first-page":"4019","DOI":"10.1200\/JCO.2024.42.16_suppl.4019","volume":"42","author":"Q Zhang","year":"2024","unstructured":"Zhang, Q. et al. Phase I study of C-CAR031, a GPC3-specific TGF\u03b2RIIDN armored autologous CAR-T, in patients with advanced hepatocellular carcinoma (HCC). J. Clin. Oncol. 42, 4019 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2780_CR72","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1002\/cac2.12472","volume":"43","author":"Y Shi","year":"2023","unstructured":"Shi, Y. et al. Combined local therapy and CAR-GPC3 T-cell therapy in advanced hepatocellular carcinoma: a proof-of-concept treatment strategy. Cancer Commun. 43, 1064\u20131068 (2023).","journal-title":"Cancer Commun."},{"key":"2780_CR73","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","volume":"375","author":"CE Brown","year":"2016","unstructured":"Brown, C. E. et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N. Engl. J. Med. 375, 2561\u20132569 (2016).","journal-title":"N. Engl. J. Med."},{"key":"2780_CR74","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","volume":"30","author":"SJ Bagley","year":"2024","unstructured":"Bagley, S. J. et al. Intrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: phase 1 trial interim results. Nat. Med. 30, 1320\u20131329 (2024).","journal-title":"Nat. Med."},{"key":"2780_CR75","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","volume":"603","author":"RG Majzner","year":"2022","unstructured":"Majzner, R. G. et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature 603, 934\u2013941 (2022).","journal-title":"Nature"},{"key":"2780_CR76","doi-asserted-by":"publisher","first-page":"8517","DOI":"10.1200\/JCO.2025.43.16_suppl.8517","volume":"43","author":"S Wei","year":"2025","unstructured":"Wei, S. et al. Hypoxia-responsive CEA CAR-T cells therapy for relapsed or refractory non-small cell lung cancer: A single-arm, open-label, phase I trial. J. Clin. Oncol. 43, 8517 (2025).","journal-title":"J. Clin. Oncol."},{"key":"2780_CR77","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","volume":"20","author":"CL Flugel","year":"2023","unstructured":"Flugel, C. L. et al. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat. Rev. Clin. Oncol. 20, 49\u201362 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2780_CR78","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41568-019-0162-4","volume":"19","author":"CC Smith","year":"2019","unstructured":"Smith, C. C. et al. Alternative tumour-specific antigens. Nat. Rev. Cancer 19, 465\u2013478 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"2780_CR79","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02386-8","volume":"24","author":"SS Azeez","year":"2025","unstructured":"Azeez, S. S. et al. Advancing CAR-based cell therapies for solid tumours: challenges, therapeutic strategies, and perspectives. Mol. Cancer 24, 191 (2025).","journal-title":"Mol. Cancer"},{"key":"2780_CR80","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1016\/j.ymthe.2023.06.006","volume":"31","author":"AR Haas","year":"2023","unstructured":"Haas, A. R. et al. Two cases of severe pulmonary toxicity from highly active mesothelin-directed CAR T cells. Mol. Ther. 31, 2309\u20132325 (2023).","journal-title":"Mol. Ther."},{"key":"2780_CR81","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1038\/s41571-025-01075-1","volume":"22","author":"J Li","year":"2025","unstructured":"Li, J. et al. Optimizing CAR T cell therapy for solid tumours: a clinical perspective. Nat. Rev. Clin. Oncol. 22, 953\u2013968 (2025).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2780_CR82","doi-asserted-by":"publisher","first-page":"5345","DOI":"10.1182\/blood-2019-129600","volume":"134","author":"P Horna","year":"2019","unstructured":"Horna, P., Nowakowski, G., Endell, J. & Boxhammer, R. Comparative assessment of surface CD19 and CD20 expression on B-cell lymphomas from clinical biopsies: implications for targeted therapies. Blood 134, 5345 (2019).","journal-title":"Blood"},{"key":"2780_CR83","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1038\/s41591-024-03037-z","volume":"30","author":"C Qi","year":"2024","unstructured":"Qi, C. et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results. Nat. Med. 30, 2224\u20132234 (2024).","journal-title":"Nat. Med."},{"key":"2780_CR84","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/s43018-021-00244-2","volume":"2","author":"K Hirabayashi","year":"2021","unstructured":"Hirabayashi, K. et al. Dual targeting CAR-T cells with optimal costimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors. Nat. Cancer 2, 904\u2013918 (2021).","journal-title":"Nat. Cancer"},{"key":"2780_CR85","first-page":"372","volume":"16","author":"NN Shah","year":"2019","unstructured":"Shah, N. N. & Fry, T. J. Mechanisms of resistance to CAR T cell therapy. Nat. Rev. Clin. Oncol. 16, 372\u2013385 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2780_CR86","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa0984","volume":"9","author":"DM O\u2019Rourke","year":"2017","unstructured":"O\u2019Rourke, D. M. et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci. Transl. Med. 9, eaaa0984 (2017).","journal-title":"Sci. Transl. Med."},{"key":"2780_CR87","doi-asserted-by":"publisher","first-page":"856","DOI":"10.2967\/jnumed.123.267110","volume":"65","author":"C Qi","year":"2024","unstructured":"Qi, C. et al. (68)Ga-NC-BCH whole-body PET imaging rapidly targets Claudin18.2 in lesions in gastrointestinal cancer patients. J. Nucl. Med. 65, 856\u2013863 (2024).","journal-title":"J. Nucl. Med."},{"key":"2780_CR88","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s44178-025-00205-0","volume":"4","author":"Y Nie","year":"2025","unstructured":"Nie, Y. Breaking barriers: the emerging promise of CAR-T cell therapy in solid tumors. Holist. Integr. Oncol. 4, 70 (2025).","journal-title":"Holist. Integr. Oncol."},{"key":"2780_CR89","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41586-023-05778-2","volume":"615","author":"AM Tousley","year":"2023","unstructured":"Tousley, A. M. et al. Co-opting signalling molecules enables logic-gated control of CAR T cells. Nature 615, 507\u2013516 (2023).","journal-title":"Nature"},{"key":"2780_CR90","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1038\/s41551-024-01287-3","volume":"8","author":"SE James","year":"2024","unstructured":"James, S. E. et al. Leucine zipper-based immunomagnetic purification of CAR T cells displaying multiple receptors. Nat. Biomed. Eng. 8, 1592\u20131614 (2024).","journal-title":"Nat. Biomed. Eng."},{"key":"2780_CR91","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41577-025-01174-1","volume":"25","author":"YR Li","year":"2025","unstructured":"Li, Y. R., Zhu, Y., Halladay, T. & Yang, L. In vivo CAR engineering for immunotherapy. Nat. Rev. Immunol. 25, 725\u2013744 (2025).","journal-title":"Nat. Rev. Immunol."},{"key":"2780_CR92","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41573-025-01291-5","volume":"25","author":"A Bot","year":"2026","unstructured":"Bot, A. et al. In vivo chimeric antigen receptor (CAR)-T cell therapy. Nat. Rev. Drug Discov. 25, 116\u2013137 (2026).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2780_CR93","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1001\/jamaoncol.2024.3891","volume":"10","author":"N Chen","year":"2024","unstructured":"Chen, N. et al. Chimeric antigen receptor T cells targeting CD19 and GCC in metastatic colorectal cancer: a nonrandomized clinical trial. JAMA Oncol. 10, 1532\u20131536 (2024).","journal-title":"JAMA Oncol."},{"key":"2780_CR94","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.ccell.2025.11.009","volume":"44","author":"G Yagel","year":"2026","unstructured":"Yagel, G. et al. Tumor-antigen-independent targeting of solid tumors by armored macrophage-directed anti-TREM2 CAR T cells. Cancer Cell 44, 519\u2013533 (2026).","journal-title":"Cancer Cell"},{"key":"2780_CR95","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1016\/j.cell.2025.02.035","volume":"188","author":"L Liu","year":"2025","unstructured":"Liu, L. et al. Engineering sonogenetic EchoBack-CAR T cells. Cell 188, 2621\u20132636.e2620 (2025).","journal-title":"Cell"},{"key":"2780_CR96","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/s41586-025-09212-7","volume":"644","author":"AXY Chen","year":"2025","unstructured":"Chen, A. X. Y. et al. Rewiring endogenous genes in CAR T cells for tumour-restricted payload delivery. Nature 644, 241\u2013251 (2025).","journal-title":"Nature"},{"key":"2780_CR97","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13045-025-01745-8","volume":"18","author":"J Su","year":"2025","unstructured":"Su, J. et al. Genome-edited allogeneic CAR-T cells: the next generation of cancer immunotherapies. J. Hematol. Oncol. 18, 90 (2025).","journal-title":"J. Hematol. Oncol."},{"key":"2780_CR98","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nbt.4086","volume":"36","author":"K Adachi","year":"2018","unstructured":"Adachi, K. et al. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nat. Biotechnol. 36, 346\u2013351 (2018).","journal-title":"Nat. Biotechnol."},{"key":"2780_CR99","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1200\/JCO.2024.42.16_suppl.2543","volume":"42","author":"TE Nakajima","year":"2024","unstructured":"Nakajima, T. E. et al. Updated results from first-in-human phase 1 dose-escalation trial of TAK-102, a GPC3-targeted armored CAR T cells, in patients with advanced solid tumors. J. Clin. Oncol. 42, 2543 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2780_CR100","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41417-019-0104-z","volume":"27","author":"SC Katz","year":"2020","unstructured":"Katz, S. C. et al. HITM-SIR: phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy and selective internal radiation therapy for CEA+ liver metastases. Cancer Gene Ther. 27, 341\u2013355 (2020).","journal-title":"Cancer Gene Ther."},{"key":"2780_CR101","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001097","volume":"8","author":"SC Katz","year":"2020","unstructured":"Katz, S. C. et al. HITM-SURE: hepatic immunotherapy for metastases phase Ib anti-CEA CAR-T study utilizing pressure enabled drug delivery. J. Immunother. Cancer 8, e001097 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"2780_CR102","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1158\/2643-3230.BCD-21-0084","volume":"2","author":"M Abou-El-Enein","year":"2021","unstructured":"Abou-El-Enein, M. et al. Scalable manufacturing of CAR T cells for cancer immunotherapy. Blood Cancer Discov. 2, 408\u2013422 (2021).","journal-title":"Blood Cancer Discov."},{"key":"2780_CR103","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1038\/s41587-023-01981-8","volume":"41","author":"M Elsallab","year":"2023","unstructured":"Elsallab, M. & Maus, M. V. Expanding access to CAR T cell therapies through local manufacturing. Nat. Biotechnol. 41, 1698\u20131708 (2023).","journal-title":"Nat. Biotechnol."},{"key":"2780_CR104","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner, R. C. & Sterner, R. M. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 11, 69 (2021).","journal-title":"Blood Cancer J."},{"key":"2780_CR105","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/s41571-022-00607-3","volume":"19","author":"L Amini","year":"2022","unstructured":"Amini, L. et al. Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion. Nat. Rev. Clin. Oncol. 19, 342\u2013355 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2780_CR106","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","volume":"614","author":"L Labanieh","year":"2023","unstructured":"Labanieh, L. & Mackall, C. L. CAR immune cells: design principles, resistance and the next generation. Nature 614, 635\u2013648 (2023).","journal-title":"Nature"},{"key":"2780_CR107","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1016\/j.ymthe.2020.05.005","volume":"28","author":"S Agarwal","year":"2020","unstructured":"Agarwal, S. et al. In vivo generation of CAR T cells selectively in human CD4(+) lymphocytes. Mol. Ther. 28, 1783\u20131794 (2020).","journal-title":"Mol. Ther."},{"key":"2780_CR108","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.omtm.2022.06.004","volume":"26","author":"N Ho","year":"2022","unstructured":"Ho, N. et al. In vivo generation of CAR T cells in the presence of human myeloid cells. Mol. Ther. Methods Clin. Dev. 26, 144\u2013156 (2022).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"2780_CR109","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.1016\/j.ymthe.2021.06.004","volume":"29","author":"I Tomb\u00e1cz","year":"2021","unstructured":"Tomb\u00e1cz, I. et al. Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs. Mol. Ther. 29, 3293\u20133304 (2021).","journal-title":"Mol. Ther."},{"key":"2780_CR110","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202304378","volume":"20","author":"MM Billingsley","year":"2024","unstructured":"Billingsley, M. M. et al. In vivo mRNA CAR T cell engineering via targeted ionizable lipid nanoparticles with extrahepatic tropism. Small 20, e2304378 (2024).","journal-title":"Small"},{"key":"2780_CR111","doi-asserted-by":"publisher","first-page":"121339","DOI":"10.1016\/j.biomaterials.2021.121339","volume":"281","author":"A Kheirolomoom","year":"2022","unstructured":"Kheirolomoom, A. et al. In situ T-cell transfection by anti-CD3-conjugated lipid nanoparticles leads to T-cell activation, migration, and phenotypic shift. Biomaterials 281, 121339 (2022).","journal-title":"Biomaterials"},{"key":"2780_CR112","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.jconrel.2022.08.033","volume":"350","author":"JE Zhou","year":"2022","unstructured":"Zhou, J. E. et al. Lipid nanoparticles produce chimeric antigen receptor T cells with interleukin-6 knockdown in vivo. J. Control Release 350, 298\u2013307 (2022).","journal-title":"J. Control Release"},{"key":"2780_CR113","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002737","volume":"9","author":"JT Huckaby","year":"2021","unstructured":"Huckaby, J. T. et al. Bispecific binder redirected lentiviral vector enables in vivo engineering of CAR-T cells. J. Immunother. Cancer 9, e002737 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"2780_CR114","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006292","volume":"11","author":"KR Michels","year":"2023","unstructured":"Michels, K. R. et al. Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering. J. Immunother. Cancer 11, e006292 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"2780_CR115","doi-asserted-by":"publisher","first-page":"2302992","DOI":"10.1002\/advs.202302992","volume":"10","author":"FT Charitidis","year":"2023","unstructured":"Charitidis, F. T. et al. CAR gene delivery by T-cell targeted lentiviral vectors is enhanced by rapamycin induced reduction of antiviral mechanisms. Adv. Sci. 10, 2302992 (2023).","journal-title":"Adv. Sci."},{"key":"2780_CR116","doi-asserted-by":"publisher","first-page":"4937","DOI":"10.1016\/j.ymthe.2025.06.036","volume":"33","author":"JI Andorko","year":"2025","unstructured":"Andorko, J. I. et al. Targeted in vivo delivery of genetic medicines utilizing an engineered lentiviral vector platform results in CAR T and NK cell generation. Mol. Ther. 33, 4937\u20134952 (2025).","journal-title":"Mol. Ther."},{"key":"2780_CR117","doi-asserted-by":"publisher","first-page":"TPS2681","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS2681","volume":"43","author":"JR Garcia","year":"2025","unstructured":"Garcia, J. R. A phase I, multicenter, open-label study of UB-VV111 in combination with rapamycin in relapsed\/refractory CD19+ B-cell malignancies. J. Clin. Oncol. 43, TPS2681 (2025).","journal-title":"J. Clin. Oncol."},{"key":"2780_CR118","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1126\/science.ads8473","volume":"388","author":"TL Hunter","year":"2025","unstructured":"Hunter, T. L. et al. In vivo CAR T cell generation to treat cancer and autoimmune disease. Science 388, 1311\u20131317 (2025).","journal-title":"Science"},{"key":"2780_CR119","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1182\/blood-2024-207566","volume":"144","author":"V Lemgart","year":"2024","unstructured":"Lemgart, V. et al. In vitro and in vivo activity of a lipid nanoparticle system for the in vivo generation of CAR T cells. Blood 144, 3421 (2024).","journal-title":"Blood"},{"key":"2780_CR120","doi-asserted-by":"publisher","first-page":"105266","DOI":"10.1016\/j.ebiom.2024.105266","volume":"106","author":"TA Bui","year":"2024","unstructured":"Bui, T. A. et al. Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment. EBioMedicine 106, 105266 (2024).","journal-title":"EBioMedicine"},{"key":"2780_CR121","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/S0140-6736(25)01030-X","volume":"406","author":"J Xu","year":"2025","unstructured":"Xu, J. et al. In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma. Lancet 406, 228\u2013231 (2025).","journal-title":"Lancet"},{"key":"2780_CR122","doi-asserted-by":"publisher","first-page":"101805","DOI":"10.1016\/j.nantod.2023.101805","volume":"49","author":"Y Liu","year":"2023","unstructured":"Liu, Y. et al. In situ MUC1-specific CAR engineering of tumor-supportive macrophages stimulates tumoricidal immunity against pancreatic adenocarcinoma. Nano Today 49, 101805 (2023).","journal-title":"Nano Today"},{"key":"2780_CR123","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.jconrel.2023.07.021","volume":"360","author":"Z Yang","year":"2023","unstructured":"Yang, Z. et al. Dual mRNA co-delivery for in situ generation of phagocytosis-enhanced CAR macrophages augments hepatocellular carcinoma immunotherapy. J. Control Release 360, 718\u2013733 (2023).","journal-title":"J. Control Release"},{"key":"2780_CR124","doi-asserted-by":"publisher","first-page":"2312038","DOI":"10.1002\/adfm.202312038","volume":"34","author":"AJ Mukalel","year":"2024","unstructured":"Mukalel, A. J. et al. Oxidized mRNA lipid nanoparticles for in situ chimeric antigen receptor monocyte engineering. Adv. Funct. Mater. 34, 2312038 (2024).","journal-title":"Adv. Funct. Mater."},{"key":"2780_CR125","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-023-01810-9","volume":"21","author":"L Gao","year":"2023","unstructured":"Gao, L. et al. Convection-enhanced delivery of nanoencapsulated gene locoregionally yielding ErbB2\/Her2-specific CAR-macrophages for brainstem glioma immunotherapy. J. Nanobiotechnology. 21, 56 (2023).","journal-title":"J. Nanobiotechnology."},{"key":"2780_CR126","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn1128","volume":"14","author":"C Chen","year":"2022","unstructured":"Chen, C. et al. Intracavity generation of glioma stem cell-specific CAR macrophages primes locoregional immunity for postoperative glioblastoma therapy. Sci. Transl. Med. 14, eabn1128 (2022).","journal-title":"Sci. Transl. Med."},{"key":"2780_CR127","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nri2887","volume":"11","author":"PA van der Merwe","year":"2011","unstructured":"van der Merwe, P. A. & Dushek, O. Mechanisms for T cell receptor triggering. Nat. Rev. Immunol. 11, 47\u201355 (2011).","journal-title":"Nat. Rev. Immunol."},{"key":"2780_CR128","doi-asserted-by":"publisher","first-page":"eadf3700","DOI":"10.1126\/sciadv.adf3700","volume":"9","author":"E Baulu","year":"2023","unstructured":"Baulu, E., Gardet, C., Chuvin, N. & Depil, S. TCR-engineered T cell therapy in solid tumors: State of the art and perspectives. Sci. Adv. 9, eadf3700 (2023).","journal-title":"Sci. Adv."},{"key":"2780_CR129","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/334156a0","volume":"334","author":"H Bl\u00fcthmann","year":"1988","unstructured":"Bl\u00fcthmann, H. et al. T-cell-specific deletion of T-cell receptor transgenes allows functional rearrangement of endogenous alpha- and beta-genes. Nature 334, 156\u2013159 (1988).","journal-title":"Nature"},{"key":"2780_CR130","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/S0092-8674(02)01194-7","volume":"111","author":"ME Call","year":"2002","unstructured":"Call, M. E., Pyrdol, J., Wiedmann, M. & Wucherpfennig, K. W. The organizing principle in the formation of the T cell receptor-CD3 complex. Cell 111, 967\u2013979 (2002).","journal-title":"Cell"},{"key":"2780_CR131","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.tibs.2017.11.008","volume":"43","author":"AH Courtney","year":"2018","unstructured":"Courtney, A. H., Lo, W. L. & Weiss, A. TCR signaling: mechanisms of initiation and propagation. Trends Biochem. Sci. 43, 108\u2013123 (2018).","journal-title":"Trends Biochem. Sci."},{"key":"2780_CR132","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/s12276-020-0435-8","volume":"52","author":"JR Hwang","year":"2020","unstructured":"Hwang, J. R., Byeon, Y., Kim, D. & Park, S. G. Recent insights of T cell receptor-mediated signaling pathways for T cell activation and development. Exp. Mol. Med. 52, 750\u2013761 (2020).","journal-title":"Exp. Mol. Med."},{"key":"2780_CR133","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/imr.12772","volume":"290","author":"SS Chandran","year":"2019","unstructured":"Chandran, S. S. & Klebanoff, C. A. T cell receptor-based cancer immunotherapy: emerging efficacy and pathways of resistance. Immunol. Rev. 290, 127\u2013147 (2019).","journal-title":"Immunol. Rev."},{"key":"2780_CR134","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40164-022-00291-0","volume":"11","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y., Liu, Z., Wei, W. & Li, Y. TCR engineered T cells for solid tumor immunotherapy. Exp. Hematol. Oncol. 11, 38 (2022).","journal-title":"Exp. Hematol. Oncol."},{"key":"2780_CR135","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1016\/j.ymthe.2024.07.028","volume":"32","author":"GSF Anderson","year":"2024","unstructured":"Anderson, G. S. F. & Chapman, M. A. T cell-redirecting therapies in hematological malignancies: current developments and novel strategies for improved targeting. Mol. Ther. 32, 2856\u20132891 (2024).","journal-title":"Mol. Ther."},{"key":"2780_CR136","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1038\/s41375-023-01976-z","volume":"37","author":"K Yun","year":"2023","unstructured":"Yun, K., Siegler, E. L. & Kenderian, S. S. Who wins the combat, CAR or TCR? Leukemia 37, 1953\u20131962 (2023).","journal-title":"Leukemia"},{"key":"2780_CR137","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S1074-7613(00)80483-5","volume":"4","author":"Y Sykulev","year":"1996","unstructured":"Sykulev, Y. et al. Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response. Immunity 4, 565\u2013571 (1996).","journal-title":"Immunity"},{"key":"2780_CR138","doi-asserted-by":"publisher","first-page":"E2068","DOI":"10.1073\/pnas.1716266115","volume":"115","author":"AJ Davenport","year":"2018","unstructured":"Davenport, A. J. et al. Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity. Proc. Natl. Acad. Sci. USA 115, E2068\u2013e2076 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2780_CR139","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s41423-026-01391-1","volume":"23","author":"X Li","year":"2026","unstructured":"Li, X. et al. Lytic IFN\u03b3 is stored in cytotoxic granules and coreleased with granzyme B to mediate cytotoxic T lymphocyte killing. Cell Mol. Immunol. 23, 400\u2013416 (2026).","journal-title":"Cell Mol. Immunol."},{"key":"2780_CR140","doi-asserted-by":"publisher","first-page":"507","DOI":"10.4049\/jimmunol.163.1.507","volume":"163","author":"TM Clay","year":"1999","unstructured":"Clay, T. M. et al. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J. Immunol. 163, 507\u2013513 (1999).","journal-title":"J. Immunol."},{"key":"2780_CR141","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1126\/science.1129003","volume":"314","author":"RA Morgan","year":"2006","unstructured":"Morgan, R. A. et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126\u2013129 (2006).","journal-title":"Science"},{"key":"2780_CR142","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ads5589","volume":"11","author":"G Croce","year":"2025","unstructured":"Croce, G. et al. Phage display enables machine learning discovery of cancer antigen-specific TCRs. Sci. Adv. 11, eads5589 (2025).","journal-title":"Sci. Adv."},{"key":"2780_CR143","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40425-017-0216-7","volume":"5","author":"G Kueberuwa","year":"2017","unstructured":"Kueberuwa, G. et al. CCR7(+) selected gene-modified T cells maintain a central memory phenotype and display enhanced persistence in peripheral blood in vivo. J. Immunother. Cancer 5, 14 (2017).","journal-title":"J. Immunother. Cancer"},{"key":"2780_CR144","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","volume":"385","author":"P Nathan","year":"2021","unstructured":"Nathan, P. et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N. Engl. J. Med. 385, 1196\u20131206 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2780_CR145","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-60394-0","volume":"16","author":"F Mazziotta","year":"2025","unstructured":"Mazziotta, F. et al. A phase I\/II trial of WT1-specific TCR gene therapy for patients with acute myeloid leukemia and active disease post-allogeneic hematopoietic cell transplantation: skewing towards NK-like phenotype impairs T cell function and persistence. Nat. Commun. 16, 5214 (2025).","journal-title":"Nat. Commun."},{"key":"2780_CR146","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004409","volume":"10","author":"RA van Amerongen","year":"2022","unstructured":"van Amerongen, R. A. et al. WT1-specific TCRs directed against newly identified peptides install antitumor reactivity against acute myeloid leukemia and ovarian carcinoma. J. Immunother. Cancer 10, e004409 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"2780_CR147","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1182\/blood-2017-06-791202","volume":"130","author":"I Tawara","year":"2017","unstructured":"Tawara, I. et al. Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS. Blood 130, 1985\u20131994 (2017).","journal-title":"Blood"},{"key":"2780_CR148","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/s41568-025-00857-0","volume":"25","author":"Z Foldvari","year":"2025","unstructured":"Foldvari, Z. et al. Targeting the roots of myeloid malignancies with T cell receptors. Nat. Rev. Cancer 25, 965\u2013985 (2025).","journal-title":"Nat. Rev. Cancer"},{"key":"2780_CR149","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/s41591-019-0472-9","volume":"25","author":"AG Chapuis","year":"2019","unstructured":"Chapuis, A. G. et al. T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant. Nat. Med. 25, 1064\u20131072 (2019).","journal-title":"Nat. Med."},{"key":"2780_CR150","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1200\/JCO.2010.32.2537","volume":"29","author":"PF Robbins","year":"2011","unstructured":"Robbins, P. F. et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29, 917\u2013924 (2011).","journal-title":"J. Clin. Oncol."},{"key":"2780_CR151","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1158\/1078-0432.CCR-14-2708","volume":"21","author":"PF Robbins","year":"2015","unstructured":"Robbins, P. F. et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1\u2013reactive T-cell receptor: long-term follow-up and correlates with response. Clin. Cancer Res. 21, 1019\u20131027 (2015).","journal-title":"Clin. Cancer Res."},{"key":"2780_CR152","doi-asserted-by":"publisher","first-page":"101133","DOI":"10.1016\/j.xcrm.2023.101133","volume":"4","author":"Q Pan","year":"2023","unstructured":"Pan, Q. et al. Phase 1 clinical trial to assess safety and efficacy of NY-ESO-1-specific TCR T cells in HLA-A\u221702:01 patients with advanced soft tissue sarcoma. Cell Rep. Med. 4, 101133 (2023).","journal-title":"Cell Rep. Med."},{"key":"2780_CR153","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1158\/1078-0432.CCR-25-0595","volume":"31","author":"KK Barnett","year":"2025","unstructured":"Barnett, K. K. et al. FDA approval summary: afamitresgene autoleucel for adults with HLA-restricted, MAGE-A4\u2013positive unresectable or metastatic synovial sarcoma after prior chemotherapy. Clin. Cancer Res. 31, 3112\u20133117 (2025).","journal-title":"Clin. Cancer Res."},{"key":"2780_CR154","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/S0140-6736(24)00319-2","volume":"403","author":"SP D\u2019Angelo","year":"2024","unstructured":"D\u2019Angelo, S. P. et al. Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial. Lancet 403, 1460\u20131471 (2024).","journal-title":"Lancet"},{"key":"2780_CR155","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1038\/s41591-025-03650-6","volume":"31","author":"M Wermke","year":"2025","unstructured":"Wermke, M. et al. Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial. Nat. Med. 31, 2365\u20132374 (2025).","journal-title":"Nat. Med."},{"key":"2780_CR156","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/s41591-020-01225-1","volume":"27","author":"NB Nagarsheth","year":"2021","unstructured":"Nagarsheth, N. B. et al. TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers. Nat. Med. 27, 419\u2013425 (2021).","journal-title":"Nat. Med."},{"key":"2780_CR157","doi-asserted-by":"publisher","first-page":"6047","DOI":"10.1200\/JCO.2023.41.16_suppl.6047","volume":"41","author":"Q Jia","year":"2023","unstructured":"Jia, Q. et al. TCR-T cells armored with immune checkpoint blockade in EBV-positive nasopharyngeal carcinoma: The first-in-human phase 1\/2 trial. J. Clin. Oncol. 41, 6047 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2780_CR158","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1038\/s41590-025-02252-1","volume":"26","author":"MS Eggeb\u00f8","year":"2025","unstructured":"Eggeb\u00f8, M. S. et al. TCR-engineered T cells targeting a shared \u03b2-catenin mutation eradicate solid tumors. Nat. Immunol. 26, 1726\u20131736 (2025).","journal-title":"Nat. Immunol."},{"key":"2780_CR159","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1056\/NEJMoa2119662","volume":"386","author":"R Leidner","year":"2022","unstructured":"Leidner, R. et al. Neoantigen T-cell receptor gene therapy in pancreatic cancer. N. Engl. J. Med. 386, 2112\u20132119 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2780_CR160","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1038\/s41591-024-03109-0","volume":"30","author":"M Parkhurst","year":"2024","unstructured":"Parkhurst, M. et al. Adoptive transfer of personalized neoantigen-reactive TCR-transduced T cells in metastatic colorectal cancer: phase 2 trial interim results. Nat. Med. 30, 2586\u20132595 (2024).","journal-title":"Nat. Med."},{"key":"2780_CR161","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1182\/blood-2006-03-013318","volume":"109","author":"MH Heemskerk","year":"2007","unstructured":"Heemskerk, M. H. et al. Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex. Blood 109, 235\u2013243 (2007).","journal-title":"Blood"},{"key":"2780_CR162","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1200\/JCO.1988.6.5.839","volume":"6","author":"SL Topalian","year":"1988","unstructured":"Topalian, S. L. et al. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J. Clin. Oncol. 6, 839\u2013853 (1988).","journal-title":"J. Clin. Oncol."},{"key":"2780_CR163","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ccell.2022.09.011","volume":"41","author":"WH Hudson","year":"2023","unstructured":"Hudson, W. H. & Wieland, A. Technology meets TILs: deciphering T cell function in the -omics era. Cancer Cell 41, 41\u201357 (2023).","journal-title":"Cancer Cell"},{"key":"2780_CR164","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008645","volume":"12","author":"N Levin","year":"2024","unstructured":"Levin, N. et al. Neoantigen-specific stimulation of tumor-infiltrating lymphocytes enables effective TCR isolation and expansion while preserving stem-like memory phenotypes. J. Immunother. Cancer 12, e008645 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"2780_CR165","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1056\/NEJM199008303230904","volume":"323","author":"SA Rosenberg","year":"1990","unstructured":"Rosenberg, S. A. et al. Gene transfer into humans\u2013immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N. Engl. J. Med. 323, 570\u2013578 (1990).","journal-title":"N. Engl. J. Med."},{"key":"2780_CR166","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1084\/jem.156.2.385","volume":"156","author":"TJ Eberlein","year":"1982","unstructured":"Eberlein, T. J., Rosenstein, M. & Rosenberg, S. A. Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2. J. Exp. Med. 156, 385\u2013397 (1982).","journal-title":"J. Exp. Med."},{"key":"2780_CR167","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","volume":"319","author":"SA Rosenberg","year":"1988","unstructured":"Rosenberg, S. A. et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N. Engl. J. Med. 319, 1676\u20131680 (1988).","journal-title":"N. Engl. J. Med."},{"key":"2780_CR168","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1158\/1078-0432.CCR-10-0041","volume":"16","author":"MJ Besser","year":"2010","unstructured":"Besser, M. J. et al. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin. Cancer Res. 16, 2646\u20132655 (2010).","journal-title":"Clin. Cancer Res."},{"key":"2780_CR169","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03444-1","volume":"20","author":"K Okamura","year":"2022","unstructured":"Okamura, K. et al. Lymphocytes in tumor-draining lymph nodes co-cultured with autologous tumor cells for adoptive cell therapy. J. Transl. Med. 20, 241 (2022).","journal-title":"J. Transl. Med."},{"key":"2780_CR170","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1146\/annurev-immunol-042617-053402","volume":"37","author":"TN Schumacher","year":"2019","unstructured":"Schumacher, T. N., Scheper, W. & Kvistborg, P. Cancer neoantigens. Annu. Rev. Immunol. 37, 173\u2013200 (2019).","journal-title":"Annu. Rev. Immunol."},{"key":"2780_CR171","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41591-018-0040-8","volume":"24","author":"N Zacharakis","year":"2018","unstructured":"Zacharakis, N. et al. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat. Med. 24, 724\u2013730 (2018).","journal-title":"Nat. Med."},{"key":"2780_CR172","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","volume":"375","author":"E Tran","year":"2016","unstructured":"Tran, E. et al. T-cell transfer therapy targeting mutant KRAS in cancer. N. Engl. J. Med. 375, 2255\u20132262 (2016).","journal-title":"N. Engl. J. Med."},{"key":"2780_CR173","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1126\/science.abl5447","volume":"375","author":"FJ Lowery","year":"2022","unstructured":"Lowery, F. J. et al. Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers. Science 375, 877\u2013884 (2022).","journal-title":"Science"},{"key":"2780_CR174","doi-asserted-by":"publisher","first-page":"14639","DOI":"10.1073\/pnas.0405730101","volume":"101","author":"SA Rosenberg","year":"2004","unstructured":"Rosenberg, S. A. & Dudley, M. E. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc. Natl. Acad. Sci. USA 101, 14639\u201314645 (2004).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2780_CR175","doi-asserted-by":"publisher","first-page":"e2409356","DOI":"10.1002\/advs.202409356","volume":"11","author":"W Hu","year":"2024","unstructured":"Hu, W., Bian, Y. & Ji, H. TIL therapy in lung cancer: current progress and perspectives. Adv. Sci. 11, e2409356 (2024).","journal-title":"Adv. Sci."},{"key":"2780_CR176","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05826-z","volume":"22","author":"H Hong","year":"2024","unstructured":"Hong, H. et al. Clinical trial landscape for TIL therapy: emerging insights and future directions in oncology. J. Transl. Med. 22, 1008 (2024).","journal-title":"J. Transl. Med."},{"key":"2780_CR177","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1093\/annonc\/mdz398","volume":"30","author":"U Dafni","year":"2019","unstructured":"Dafni, U. et al. Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis. Ann. Oncol. 30, 1902\u20131913 (2019).","journal-title":"Ann. Oncol."},{"key":"2780_CR178","doi-asserted-by":"publisher","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","volume":"17","author":"SA Rosenberg","year":"2011","unstructured":"Rosenberg, S. A. et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17, 4550\u20134557 (2011).","journal-title":"Clin. Cancer Res."},{"key":"2780_CR179","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41571-023-00848-w","volume":"21","author":"S Klobuch","year":"2024","unstructured":"Klobuch, S., Seijkens, T. T. P., Schumacher, T. N. & Haanen, J. Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma. Nat. Rev. Clin. Oncol. 21, 173\u2013184 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2780_CR180","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1200\/JCO.2019.37.15_suppl.2538","volume":"37","author":"AA Jazaeri","year":"2019","unstructured":"Jazaeri, A. A. et al. Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma. J. Clin. Oncol. 37, 2538 (2019).","journal-title":"J. Clin. Oncol."},{"key":"2780_CR181","doi-asserted-by":"publisher","first-page":"CT056","DOI":"10.1158\/1538-7445.AM2020-CT056","volume":"80","author":"B Creelan","year":"2020","unstructured":"Creelan, B. et al. Durable complete responses to adoptive cell transfer using tumor infiltrating lymphocytes (TIL) in non-small cell lung cancer (NSCLC): a phase I trial. Cancer Res. 80, CT056 (2020).","journal-title":"Cancer Res."},{"key":"2780_CR182","doi-asserted-by":"publisher","first-page":"217281","DOI":"10.1016\/j.canlet.2024.217281","volume":"605","author":"DR Plaugher","year":"2024","unstructured":"Plaugher, D. R. et al. Therapeutic potential of tumor-infiltrating lymphocytes in non-small cell lung cancer. Cancer Lett. 605, 217281 (2024).","journal-title":"Cancer Lett."},{"key":"2780_CR183","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1038\/s41591-025-03627-5","volume":"31","author":"FJ Lowery","year":"2025","unstructured":"Lowery, F. J. et al. Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers: a phase 2 trial. Nat. Med. 31, 1994\u20132003 (2025).","journal-title":"Nat. Med."},{"key":"2780_CR184","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1159\/000544163","volume":"14","author":"T Xia","year":"2025","unstructured":"Xia, T. et al. Autologous tumor-infiltrating lymphocyte infusion plus anti-programmed cell death protein 1 therapy to cure advanced hepatocellular carcinoma following palliative hepatectomy. Liver Cancer 14, 497\u2013505 (2025).","journal-title":"Liver Cancer"},{"key":"2780_CR185","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008735","volume":"12","author":"A Betof Warner","year":"2024","unstructured":"Betof Warner, A. et al. Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy. J. Immunother. Cancer 12, e008735 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"2780_CR186","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1126\/science.1235122","volume":"339","author":"B Vogelstein","year":"2013","unstructured":"Vogelstein, B. et al. Cancer genome landscapes. Science 339, 1546\u20131558 (2013).","journal-title":"Science"},{"key":"2780_CR187","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1200\/JCO.2012.46.6441","volume":"31","author":"ME Dudley","year":"2013","unstructured":"Dudley, M. E. et al. Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. J. Clin. Oncol. 31, 2152\u20132159 (2013).","journal-title":"J. Clin. Oncol."},{"key":"2780_CR188","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1038\/s43018-024-00798-x","volume":"5","author":"M Arias-Badia","year":"2024","unstructured":"Arias-Badia, M., Chang, R. & Fong, L. \u03b3\u03b4 T cells as critical anti-tumor immune effectors. Nat. Cancer 5, 1145\u20131157 (2024).","journal-title":"Nat. Cancer"},{"key":"2780_CR189","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41568-019-0153-5","volume":"19","author":"B Silva-Santos","year":"2019","unstructured":"Silva-Santos, B., Mensurado, S. & Coffelt, S. B. \u03b3\u03b4 T cells: pleiotropic immune effectors with therapeutic potential in cancer. Nat. Rev. Cancer 19, 392\u2013404 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"2780_CR190","doi-asserted-by":"publisher","first-page":"eabq7248","DOI":"10.1126\/science.abq7248","volume":"386","author":"A Hayday","year":"2024","unstructured":"Hayday, A., Dechanet-Merville, J., Rossjohn, J. & Silva-Santos, B. Cancer immunotherapy by \u03b3\u03b4 T cells. Science 386, eabq7248 (2024).","journal-title":"Science"},{"key":"2780_CR191","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41571-022-00722-1","volume":"20","author":"S Mensurado","year":"2023","unstructured":"Mensurado, S., Blanco-Dom\u00ednguez, R. & Silva-Santos, B. The emerging roles of \u03b3\u03b4 T cells in cancer immunotherapy. Nat. Rev. Clin. Oncol. 20, 178\u2013191 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2780_CR192","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/nri3904","volume":"15","author":"B Silva-Santos","year":"2015","unstructured":"Silva-Santos, B., Serre, K. & Norell, H. \u03b3\u03b4 T cells in cancer. Nat. Rev. Immunol. 15, 683\u2013691 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"2780_CR193","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/s41423-020-0503-y","volume":"17","author":"M Deseke","year":"2020","unstructured":"Deseke, M. & Prinz, I. Ligand recognition by the \u03b3\u03b4 TCR and discrimination between homeostasis and stress conditions. Cell Mol. Immunol. 17, 914\u2013924 (2020).","journal-title":"Cell Mol. Immunol."},{"key":"2780_CR194","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/s41423-020-0504-x","volume":"17","author":"D Kabelitz","year":"2020","unstructured":"Kabelitz, D. et al. Cancer immunotherapy with \u03b3\u03b4 T cells: many paths ahead of us. Cell Mol. Immunol. 17, 925\u2013939 (2020).","journal-title":"Cell Mol. Immunol."},{"key":"2780_CR195","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41573-019-0038-z","volume":"19","author":"Z Sebestyen","year":"2020","unstructured":"Sebestyen, Z. et al. Translating gammadelta (\u03b3\u03b4) T cells and their receptors into cancer cell therapies. Nat. Rev. Drug Discov. 19, 169\u2013184 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2780_CR196","doi-asserted-by":"publisher","first-page":"2834","DOI":"10.1182\/blood-2021-147581","volume":"138","author":"SS Neelapu","year":"2021","unstructured":"Neelapu, S. S. et al. A phase 1 safety and efficacy study of ADI-001 Anti-CD20 CAR-engineered allogeneic gamma delta (\u03b3\u03b4) T cells in adults with B cell malignancies, in monotherapy and combination with IL-2. Blood 138, 2834 (2021).","journal-title":"Blood"},{"key":"2780_CR197","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40425-019-0501-8","volume":"7","author":"M Alnaggar","year":"2019","unstructured":"Alnaggar, M. et al. Allogenic V\u03b39V\u03b42 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma. J. Immunother. Cancer 7, 36 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"2780_CR198","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.canlet.2016.07.001","volume":"380","author":"HR Mirzaei","year":"2016","unstructured":"Mirzaei, H. R. et al. Prospects for chimeric antigen receptor (CAR) \u03b3\u03b4 T cells: a potential game changer for adoptive T cell cancer immunotherapy. Cancer Lett. 380, 413\u2013423 (2016).","journal-title":"Cancer Lett."},{"key":"2780_CR199","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41375-021-01385-0","volume":"36","author":"PA Wawrzyniecka","year":"2022","unstructured":"Wawrzyniecka, P. A. et al. Chimeric antigen receptor T cells for gamma-delta T cell malignancies. Leukemia 36, 577\u2013579 (2022).","journal-title":"Leukemia"},{"key":"2780_CR200","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007955","volume":"11","author":"GP Costa","year":"2023","unstructured":"Costa, G. P., Mensurado, S. & Silva-Santos, B. Therapeutic avenues for \u03b3\u03b4 T cells in cancer. J. Immunother. Cancer 11, e007955 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"2780_CR201","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1182\/blood-2002-12-3665","volume":"102","author":"M Wilhelm","year":"2003","unstructured":"Wilhelm, M. et al. Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood 102, 200\u2013206 (2003).","journal-title":"Blood"},{"key":"2780_CR202","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13045-016-0329-3","volume":"9","author":"HH Van Acker","year":"2016","unstructured":"Van Acker, H. H. et al. Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cells. J. Hematol. Oncol. 9, 101 (2016).","journal-title":"J. Hematol. Oncol."},{"key":"2780_CR203","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/sj.bmt.1705650","volume":"39","author":"KT Godder","year":"2007","unstructured":"Godder, K. T. et al. Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant. 39, 751\u2013757 (2007).","journal-title":"Bone Marrow Transplant."},{"key":"2780_CR204","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/s41423-020-0515-7","volume":"18","author":"Y Xu","year":"2021","unstructured":"Xu, Y. et al. Allogeneic V\u03b39V\u03b42 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer. Cell Mol. Immunol. 18, 427\u2013439 (2021).","journal-title":"Cell Mol. Immunol."},{"key":"2780_CR205","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004579","volume":"10","author":"E Bruni","year":"2022","unstructured":"Bruni, E. et al. Intrahepatic CD69(+)V\u03b41 T cells re-circulate in the blood of patients with metastatic colorectal cancer and limit tumor progression. J. Immunother. Cancer 10, e004579 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"2780_CR206","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005400","volume":"10","author":"D S\u00e1nchez Mart\u00ednez","year":"2022","unstructured":"S\u00e1nchez Mart\u00ednez, D. et al. Generation and proof-of-concept for allogeneic CD123 CAR-Delta One T (DOT) cells in acute myeloid leukemia. J. Immunother. Cancer 10, e005400 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"2780_CR207","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1158\/2326-6066.CIR-18-0647","volume":"7","author":"B Di Lorenzo","year":"2019","unstructured":"Di Lorenzo, B. et al. Broad cytotoxic targeting of acute myeloid leukemia by polyclonal Delta One T cells. Cancer Immunol. Res. 7, 552\u2013558 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"2780_CR208","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/s41587-025-02629-5","volume":"43","author":"M Tarannum","year":"2025","unstructured":"Tarannum, M. et al. Engineering innate immune cells for cancer immunotherapy. Nat. Biotechnol. 43, 516\u2013533 (2025).","journal-title":"Nat. Biotechnol."},{"key":"2780_CR209","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-011890","volume":"13","author":"Z Li","year":"2025","unstructured":"Li, Z. et al. Comparative efficacy and safety of PSCA CAR-engineered V\u03b41 \u03b3\u03b4 T cells for immunotherapy of pancreatic cancer. J. Immunother. Cancer 13, e011890 (2025).","journal-title":"J. Immunother. Cancer"},{"key":"2780_CR210","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202400024","volume":"11","author":"Z Zhu","year":"2024","unstructured":"Zhu, Z. et al. mRNA-engineered CD5-CAR-\u03b3\u03b4T(CD5-) cells for the immunotherapy of T-cell acute lymphoblastic leukemia. Adv. Sci. 11, e2400024 (2024).","journal-title":"Adv. Sci."},{"key":"2780_CR211","doi-asserted-by":"publisher","first-page":"7509","DOI":"10.1200\/JCO.2022.40.16_suppl.7509","volume":"40","author":"SS Neelapu","year":"2022","unstructured":"Neelapu, S. S. et al. A phase 1 study of ADI-001: Anti-CD20 CAR-engineered allogeneic gamma delta (\u03b3\u03b4) T cells in adults with B-cell malignancies. J. Clin. Oncol. 40, 7509 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2780_CR212","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003441","volume":"9","author":"A Makkouk","year":"2021","unstructured":"Makkouk, A. et al. Off-the-shelf V\u03b41 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma. J. Immunother. Cancer 9, e003441 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"2780_CR213","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-011704","volume":"13","author":"KP Nishimoto","year":"2025","unstructured":"Nishimoto, K. P. et al. ADI-270: an armored allogeneic gamma delta T cell therapy designed to target CD70-expressing solid and hematologic malignancies. J. Immunother. Cancer 13, e011704 (2025).","journal-title":"J. Immunother. Cancer"},{"key":"2780_CR214","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.omto.2020.04.013","volume":"17","author":"WX Ang","year":"2020","unstructured":"Ang, W. X. et al. Electroporation of NKG2D RNA CAR improves V\u03b39V\u03b42 T cell responses against human solid tumor xenografts. Mol. Ther. Oncolytics 17, 421\u2013430 (2020).","journal-title":"Mol. Ther. Oncolytics"},{"key":"2780_CR215","doi-asserted-by":"publisher","first-page":"nwaf256","DOI":"10.1093\/nsr\/nwaf256","volume":"12","author":"L Chen","year":"2025","unstructured":"Chen, L. et al. Chemical engineering of \u03b3\u03b4 T cells with cancer cell-targeting antibodies for enhanced tumor immunotherapy. Natl. Sci. Rev. 12, nwaf256 (2025).","journal-title":"Natl. Sci. Rev."},{"key":"2780_CR216","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abj0835","volume":"13","author":"A De Gassart","year":"2021","unstructured":"De Gassart, A. et al. Development of ICT01, a first-in-class, anti-BTN3A antibody for activating V\u03b39V\u03b42 T cell-mediated antitumor immune response. Sci. Transl. Med. 13, eabj0835 (2021).","journal-title":"Sci. Transl. Med."},{"key":"2780_CR217","doi-asserted-by":"publisher","first-page":"S543","DOI":"10.1016\/j.annonc.2023.09.686","volume":"34","author":"S Garciaz","year":"2023","unstructured":"Garciaz, S. et al. Activation of \u03b39\u03b42 T cells by ICT01 as a novel immunotherapeutic approach for relapsed\/refractory hematologic cancers (EVICTION trial). Ann. Oncol. 34, S543 (2023).","journal-title":"Ann. Oncol."},{"key":"2780_CR218","doi-asserted-by":"publisher","DOI":"10.1126\/science.aay5516","volume":"367","author":"M Rigau","year":"2020","unstructured":"Rigau, M. et al. Butyrophilin 2A1 is essential for phosphoantigen reactivity by \u03b3\u03b4 T cells. Science 367, eaay5516 (2020).","journal-title":"Science"},{"key":"2780_CR219","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1200\/JCO.2023.41.6_suppl.153","volume":"41","author":"N Mehra","year":"2023","unstructured":"Mehra, N. et al. Early dose escalation of LAVA-1207, a novel bispecific gamma-delta T-cell engager (Gammabody), in patients with metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol. 41, 153 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2780_CR220","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202206856","volume":"10","author":"SW Huang","year":"2023","unstructured":"Huang, S. W. et al. BiTE-secreting CAR-\u03b3\u03b4T as a dual targeting strategy for the treatment of solid tumors. Adv. Sci. 10, e2206856 (2023).","journal-title":"Adv. Sci."},{"key":"2780_CR221","doi-asserted-by":"publisher","first-page":"100961","DOI":"10.1016\/j.xcrm.2023.100961","volume":"4","author":"R Lameris","year":"2023","unstructured":"Lameris, R. et al. A bispecific T cell engager recruits both type 1 NKT and V\u03b39V\u03b42-T cells for the treatment of CD1d-expressing hematological malignancies. Cell Rep. Med. 4, 100961 (2023).","journal-title":"Cell Rep. Med."},{"key":"2780_CR222","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003850","volume":"9","author":"E van Diest","year":"2021","unstructured":"van Diest, E. et al. Gamma delta TCR anti-CD3 bispecific molecules (GABs) as novel immunotherapeutic compounds. J. Immunother. Cancer 9, e003850 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"2780_CR223","doi-asserted-by":"publisher","first-page":"e70182","DOI":"10.1002\/hem3.70182","volume":"9","author":"C Agbuduwe","year":"2025","unstructured":"Agbuduwe, C., Maher, J. & Anderson, J. Harnessing the immunotherapeutic potentials of gamma delta T cells against hematological malignancies. Hemasphere 9, e70182 (2025).","journal-title":"Hemasphere"},{"key":"2780_CR224","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007981","volume":"12","author":"A Rao","year":"2024","unstructured":"Rao, A. et al. Gamma delta T cells in acute myeloid leukemia: biology and emerging therapeutic strategies. J. Immunother. Cancer 12, e007981 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"2780_CR225","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-021-03146-0","volume":"19","author":"K Alishah","year":"2021","unstructured":"Alishah, K. et al. CRISPR\/Cas9-mediated TGF\u03b2RII disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells in vitro. J. Transl. Med. 19, 482 (2021).","journal-title":"J. Transl. Med."},{"key":"2780_CR226","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1126\/science.1198687","volume":"331","author":"E Vivier","year":"2011","unstructured":"Vivier, E. et al. Innate or adaptive immunity? The example of natural killer cells. Science 331, 44\u201349 (2011).","journal-title":"Science"},{"key":"2780_CR227","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.cell.2018.07.017","volume":"174","author":"E Vivier","year":"2018","unstructured":"Vivier, E. et al. Innate lymphoid cells: 10 years on. Cell 174, 1054\u20131066 (2018).","journal-title":"Cell"},{"key":"2780_CR228","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/ni1582","volume":"9","author":"E Vivier","year":"2008","unstructured":"Vivier, E. et al. Functions of natural killer cells. Nat. Immunol. 9, 503\u2013510 (2008).","journal-title":"Nat. Immunol."},{"key":"2780_CR229","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/s41573-022-00413-7","volume":"21","author":"NA Maskalenko","year":"2022","unstructured":"Maskalenko, N. A., Zhigarev, D. & Campbell, K. S. Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders. Nat. Rev. Drug Discov. 21, 559\u2013577 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2780_CR230","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","volume":"172","author":"JP B\u00f6ttcher","year":"2018","unstructured":"B\u00f6ttcher, J. P. et al. NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Cell 172, 1022\u20131037.e1014 (2018).","journal-title":"Cell"},{"key":"2780_CR231","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s41591-018-0085-8","volume":"24","author":"KC Barry","year":"2018","unstructured":"Barry, K. C. et al. A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. Nat. Med. 24, 1178\u20131191 (2018).","journal-title":"Nat. Med."},{"key":"2780_CR232","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1182\/blood-2007-01-070656","volume":"110","author":"E Hatjiharissi","year":"2007","unstructured":"Hatjiharissi, E. et al. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V\/V and V\/F polymorphism. Blood 110, 2561\u20132564 (2007).","journal-title":"Blood"},{"key":"2780_CR233","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.jaci.2013.07.006","volume":"132","author":"KS Campbell","year":"2013","unstructured":"Campbell, K. S. & Hasegawa, J. Natural killer cell biology: an update and future directions. J. Allergy Clin. Immunol. 132, 536\u2013544 (2013).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2780_CR234","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cytogfr.2018.08.001","volume":"42","author":"B Zitti","year":"2018","unstructured":"Zitti, B. & Bryceson, Y. T. Natural killer cells in inflammation and autoimmunity. Cytokine Growth Factor Rev. 42, 37\u201346 (2018).","journal-title":"Cytokine Growth Factor Rev."},{"key":"2780_CR235","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41423-025-01297-4","volume":"22","author":"Z Shen","year":"2025","unstructured":"Shen, Z. et al. Adjusting the scope of natural killer cells in cancer therapy. Cell Mol. Immunol. 22, 699\u2013711 (2025).","journal-title":"Cell Mol. Immunol."},{"key":"2780_CR236","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1182\/blood.2022016201","volume":"141","author":"AN Courtney","year":"2023","unstructured":"Courtney, A. N., Tian, G. & Metelitsa, L. S. Natural killer T cells and other innate-like T lymphocytes as emerging platforms for allogeneic cancer cell therapy. Blood 141, 869\u2013876 (2023).","journal-title":"Blood"},{"key":"2780_CR237","doi-asserted-by":"publisher","first-page":"6287","DOI":"10.1158\/1078-0432.CCR-11-1347","volume":"17","author":"MR Parkhurst","year":"2011","unstructured":"Parkhurst, M. R., Riley, J. P., Dudley, M. E. & Rosenberg, S. A. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin. Cancer Res. 17, 6287\u20136297 (2011).","journal-title":"Clin. Cancer Res."},{"key":"2780_CR238","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41586-023-06945-1","volume":"626","author":"E Vivier","year":"2024","unstructured":"Vivier, E. et al. Natural killer cell therapies. Nature 626, 727\u2013736 (2024).","journal-title":"Nature"},{"key":"2780_CR239","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1126\/science.1068440","volume":"295","author":"L Ruggeri","year":"2002","unstructured":"Ruggeri, L. et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295, 2097\u20132100 (2002).","journal-title":"Science"},{"key":"2780_CR240","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s10238-025-01786-w","volume":"25","author":"M Khani-Eshratabadi","year":"2025","unstructured":"Khani-Eshratabadi, M. et al. Potential therapeutic roles of natural killer cells in acute myeloid leukemia: a systematic review study. Clin. Exp. Med. 25, 233 (2025).","journal-title":"Clin. Exp. Med."},{"key":"2780_CR241","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","volume":"105","author":"JS Miller","year":"2005","unstructured":"Miller, J. S. et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105, 3051\u20133057 (2005).","journal-title":"Blood"},{"key":"2780_CR242","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/j.1365-2141.2008.07340.x","volume":"143","author":"J Shi","year":"2008","unstructured":"Shi, J. et al. Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Br. J. Haematol. 143, 641\u2013653 (2008).","journal-title":"Br. J. Haematol."},{"key":"2780_CR243","doi-asserted-by":"publisher","first-page":"3474","DOI":"10.1182\/blood-2023-173162","volume":"142","author":"A Bajel","year":"2023","unstructured":"Bajel, A. et al. First-in-human study of the CD123 NK cell engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia or high risk-myelodysplasia: updated safety, efficacy, pharmacokinetics and pharmacodynamics. Blood 142, 3474 (2023).","journal-title":"Blood"},{"key":"2780_CR244","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1038\/s41591-025-03640-8","volume":"31","author":"Y Nieto","year":"2025","unstructured":"Nieto, Y. et al. Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase\u20091 trial. Nat. Med. 31, 1987\u20131993 (2025).","journal-title":"Nat. Med."},{"key":"2780_CR245","doi-asserted-by":"publisher","first-page":"879452","DOI":"10.3389\/fimmu.2022.879452","volume":"13","author":"WK Bae","year":"2022","unstructured":"Bae, W. K. et al. A phase I study of locoregional high-dose autologous natural killer cell therapy with hepatic arterial infusion chemotherapy in patients with locally advanced hepatocellular carcinoma. Front. Immunol. 13, 879452 (2022).","journal-title":"Front. Immunol."},{"key":"2780_CR246","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/pcmedi\/pbz023","volume":"2","author":"G Hong","year":"2019","unstructured":"Hong, G. et al. Effect of autologous NK cell immunotherapy on advanced lung adenocarcinoma with EGFR mutations. Precis Clin. Med. 2, 235\u2013245 (2019).","journal-title":"Precis Clin. Med."},{"key":"2780_CR247","doi-asserted-by":"publisher","first-page":"110345","DOI":"10.1016\/j.intimp.2023.110345","volume":"120","author":"NS Asl","year":"2023","unstructured":"Asl, N. S. et al. Intra-lesion injection of activated natural killer (NK) cells in recurrent malignant brain tumors. Int Immunopharmacol. 120, 110345 (2023).","journal-title":"Int Immunopharmacol."},{"key":"2780_CR248","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/ot9.0000000000000109","volume":"11","author":"J Zhou","year":"2025","unstructured":"Zhou, J. et al. Research status of colorectal cancer treatment based on natural killer cell immunotherapy. Oncol. Transl. Med. 11, 271\u2013281 (2025).","journal-title":"Oncol. Transl. Med."},{"key":"2780_CR249","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-024-02746-4","volume":"22","author":"EM McErlean","year":"2024","unstructured":"McErlean, E. M. & McCarthy, H. O. Non-viral approaches in CAR-NK cell engineering: connecting natural killer cell biology and gene delivery. J. Nanobiotechnology. 22, 552 (2024).","journal-title":"J. Nanobiotechnology."},{"key":"2780_CR250","doi-asserted-by":"publisher","first-page":"102975","DOI":"10.1016\/j.ebiom.2020.102975","volume":"59","author":"G Xie","year":"2020","unstructured":"Xie, G. et al. CAR-NK cells: A promising cellular immunotherapy for cancer. EBioMedicine 59, 102975 (2020).","journal-title":"EBioMedicine"},{"key":"2780_CR251","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41568-022-00491-0","volume":"22","author":"TJ Laskowski","year":"2022","unstructured":"Laskowski, T. J., Biederst\u00e4dt, A. & Rezvani, K. Natural killer cells in antitumour adoptive cell immunotherapy. Nat. Rev. Cancer 22, 557\u2013575 (2022).","journal-title":"Nat. Rev. Cancer"},{"key":"2780_CR252","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","volume":"30","author":"D Marin","year":"2024","unstructured":"Marin, D. et al. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19(+) B cell tumors: a phase 1\/2 trial. Nat. Med. 30, 772\u2013784 (2024).","journal-title":"Nat. Med."},{"key":"2780_CR253","doi-asserted-by":"publisher","first-page":"1454427","DOI":"10.3389\/fimmu.2024.1454427","volume":"15","author":"H Park","year":"2024","unstructured":"Park, H. et al. Efficacy and safety of natural killer cell therapy in patients with solid tumors: a systematic review and meta-analysis. Front. Immunol. 15, 1454427 (2024).","journal-title":"Front. Immunol."},{"key":"2780_CR254","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01723-z","volume":"22","author":"KM Maalej","year":"2023","unstructured":"Maalej, K. M. et al. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol. Cancer 22, 20 (2023).","journal-title":"Mol. Cancer"},{"key":"2780_CR255","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/s41423-021-00808-3","volume":"19","author":"F Fang","year":"2022","unstructured":"Fang, F. et al. Advances in NK cell production. Cell Mol. Immunol. 19, 460\u2013481 (2022).","journal-title":"Cell Mol. Immunol."},{"key":"2780_CR256","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0140-6736(24)02462-0","volume":"405","author":"A Ghobadi","year":"2025","unstructured":"Ghobadi, A. et al. Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial. Lancet 405, 127\u2013136 (2025).","journal-title":"Lancet"},{"key":"2780_CR257","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu, E. et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N. Engl. J. Med. 382, 545\u2013553 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2780_CR258","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/s43018-025-00940-3","volume":"6","author":"W Lei","year":"2025","unstructured":"Lei, W. et al. Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory\/relapsed large B-cell lymphoma: a phase 1 trial. Nat. Cancer 6, 786\u2013800 (2025).","journal-title":"Nat. Cancer"},{"key":"2780_CR259","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40164-024-00592-6","volume":"14","author":"R Huang","year":"2025","unstructured":"Huang, R. et al. Safety and efficacy of CD33-targeted CAR-NK cell therapy for relapsed\/refractory AML: preclinical evaluation and phase I trial. Exp. Hematol. Oncol. 14, 1 (2025).","journal-title":"Exp. Hematol. Oncol."},{"key":"2780_CR260","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1182\/blood-2023-173582","volume":"142","author":"CS Sauter","year":"2023","unstructured":"Sauter, C. S. et al. A phase 1 study of NKX101, a chimeric antigen receptor natural killer (CAR-NK) cell therapy, with fludarabine and cytarabine in patients with acute myeloid leukemia. Blood 142, 2097 (2023).","journal-title":"Blood"},{"key":"2780_CR261","doi-asserted-by":"publisher","first-page":"4586","DOI":"10.1182\/blood-2022-166994","volume":"140","author":"B Dhakal","year":"2022","unstructured":"Dhakal, B. et al. Interim phase I clinical data of FT576 as monotherapy and in combination with daratumumab in subjects with relapsed\/refractory multiple myeloma. Blood 140, 4586\u20134587 (2022).","journal-title":"Blood"},{"key":"2780_CR262","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-04990-6","volume":"22","author":"N Yang","year":"2024","unstructured":"Yang, N. et al. CD19\/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia. J. Transl. Med. 22, 274 (2024).","journal-title":"J. Transl. Med."},{"key":"2780_CR263","doi-asserted-by":"publisher","first-page":"5921","DOI":"10.1182\/blood-2025-5921","volume":"146","author":"M Muftuoglu","year":"2025","unstructured":"Muftuoglu, M. et al. Correlative data from an ongoing Phase 1, multicenter study of senti-202, a first-in-class, CD33 and\/or FLT3 & not endomucin (EMCN), selective off-the-shelf CAR NK cell therapy for Acute Myeloid Leukemia (AML), is consistent with its clinical activity and unique logic gated mechanism of action. Blood 146, 5921 (2025).","journal-title":"Blood"},{"key":"2780_CR264","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1093\/neuonc\/noad087","volume":"25","author":"MC Burger","year":"2023","unstructured":"Burger, M. C. et al. Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma. Neuro Oncol. 25, 2058\u20132071 (2023).","journal-title":"Neuro Oncol."},{"key":"2780_CR265","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1200\/JCO.2025.43.16_suppl.2542","volume":"43","author":"TE Seery","year":"2025","unstructured":"Seery, T. E. et al. Association of lymphopenia rescue and CA19-9 levels with overall survival following IL-15 superagonist N-803 and PD-L1 t-haNK chemo-immunotherapy for 3rd line or greater metastatic pancreatic cancer. J. Clin. Oncol. 43, 2542 (2025).","journal-title":"J. Clin. Oncol."},{"key":"2780_CR266","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.ymthe.2019.03.011","volume":"27","author":"L Xiao","year":"2019","unstructured":"Xiao, L. et al. Adoptive transfer of NKG2D CAR mRNA-engineered natural killer cells in colorectal cancer patients. Mol. Ther. 27, 1114\u20131125 (2019).","journal-title":"Mol. Ther."},{"key":"2780_CR267","doi-asserted-by":"publisher","first-page":"6543","DOI":"10.1182\/blood-2024-198684","volume":"144","author":"V Bachanova","year":"2024","unstructured":"Bachanova, V. et al. Safety and efficacy of FT522, a first-in-class, multi-antigen targeted, off-the-shelf, iPSC-derived CD19 CAR NK cell therapy with alloimmune defense receptor (ADR) in relapsed\/refractory B-cell lymphoma. Blood 144, 6543 (2024).","journal-title":"Blood"},{"key":"2780_CR268","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1158\/1538-7445.AM2024-1328","volume":"84","author":"H Ying","year":"2024","unstructured":"Ying, H. et al. AccuBaseTM (ceBE), a second-generation high-fidelity base editor, can proficiently modify genes in a human primary NK cells with minimizing off-target effect. Cancer Res. 84, 1328 (2024).","journal-title":"Cancer Res."},{"key":"2780_CR269","doi-asserted-by":"publisher","first-page":"4811","DOI":"10.1182\/blood-2023-184864","volume":"142","author":"H Rafei","year":"2023","unstructured":"Rafei, H. et al. Targeting T-cell lymphoma using CD70-directed cord blood-derived CAR-NK cells. Blood 142, 4811 (2023).","journal-title":"Blood"},{"key":"2780_CR270","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1038\/s41586-025-09087-8","volume":"643","author":"H Rafei","year":"2025","unstructured":"Rafei, H. et al. CREM is a regulatory checkpoint of CAR and IL-15 signalling in NK cells. Nature 643, 1076\u20131086 (2025).","journal-title":"Nature"},{"key":"2780_CR271","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1182\/blood.2020007748","volume":"137","author":"M Daher","year":"2021","unstructured":"Daher, M. et al. Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells. Blood 137, 624\u2013636 (2021).","journal-title":"Blood"},{"key":"2780_CR272","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","volume":"18","author":"JA Myers","year":"2021","unstructured":"Myers, J. A. & Miller, J. S. Exploring the NK cell platform for cancer immunotherapy. Nat. Rev. Clin. Oncol. 18, 85\u2013100 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2780_CR273","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1038\/s41590-022-01267-2","volume":"23","author":"A Christofides","year":"2022","unstructured":"Christofides, A. et al. The complex role of tumor-infiltrating macrophages. Nat. Immunol. 23, 1148\u20131156 (2022).","journal-title":"Nat. Immunol."},{"key":"2780_CR274","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02032-9","volume":"23","author":"N Li","year":"2024","unstructured":"Li, N. et al. A new era of cancer immunotherapy: combining revolutionary technologies for enhanced CAR-M therapy. Mol. Cancer 23, 117 (2024).","journal-title":"Mol. Cancer"},{"key":"2780_CR275","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","volume":"21","author":"A Mantovani","year":"2022","unstructured":"Mantovani, A., Allavena, P., Marchesi, F. & Garlanda, C. Macrophages as tools and targets in cancer therapy. Nat. Rev. Drug Discov. 21, 799\u2013820 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2780_CR276","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","volume":"38","author":"M Klichinsky","year":"2020","unstructured":"Klichinsky, M. et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat. Biotechnol. 38, 947\u2013953 (2020).","journal-title":"Nat. Biotechnol."},{"key":"2780_CR277","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/d41573-020-00053-9","volume":"19","author":"MT Villanueva","year":"2020","unstructured":"Villanueva, M. T. Macrophages get a CAR. Nat. Rev. Drug Discov. 19, 308 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2780_CR278","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.it.2006.12.004","volume":"28","author":"DM Underhill","year":"2007","unstructured":"Underhill, D. M. & Goodridge, H. S. The many faces of ITAMs. Trends Immunol. 28, 66\u201373 (2007).","journal-title":"Trends Immunol."},{"key":"2780_CR279","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1038\/s41551-023-01031-3","volume":"7","author":"LJ Dooling","year":"2023","unstructured":"Dooling, L. J. et al. Cooperative phagocytosis of solid tumours by macrophages triggers durable anti-tumour responses. Nat. Biomed. Eng. 7, 1081\u20131096 (2023).","journal-title":"Nat. Biomed. Eng."},{"key":"2780_CR280","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04061-2","volume":"21","author":"Y Huo","year":"2023","unstructured":"Huo, Y. et al. M1 polarization enhances the antitumor activity of chimeric antigen receptor macrophages in solid tumors. J. Transl. Med. 21, 225 (2023).","journal-title":"J. Transl. Med."},{"key":"2780_CR281","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.cmet.2019.06.001","volume":"30","author":"I Vitale","year":"2019","unstructured":"Vitale, I. et al. Macrophages and metabolism in the tumor microenvironment. Cell Metab. 30, 36\u201350 (2019).","journal-title":"Cell Metab."},{"key":"2780_CR282","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.ccr.2013.11.007","volume":"24","author":"A Casazza","year":"2013","unstructured":"Casazza, A. et al. Impeding macrophage entry into hypoxic tumor areas by Sema3A\/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity. Cancer Cell 24, 695\u2013709 (2013).","journal-title":"Cancer Cell"},{"key":"2780_CR283","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/S0070-2153(03)54015-7","volume":"54","author":"BP Toole","year":"2003","unstructured":"Toole, B. P. Emmprin (CD147), a cell surface regulator of matrix metalloproteinase production and function. Curr. Top. Dev. Biol. 54, 371\u2013389 (2003).","journal-title":"Curr. Top. Dev. Biol."},{"key":"2780_CR284","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","volume":"41","author":"K Pan","year":"2022","unstructured":"Pan, K. et al. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. J. Exp. Clin. Cancer Res. 41, 119 (2022).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2780_CR285","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1002\/cac2.70053","volume":"45","author":"M Wang","year":"2025","unstructured":"Wang, M., Qin, Z., Bian, X. W. & Shi, Y. Harnessing chimeric antigen receptor macrophages against solid tumors. Cancer Commun. 45, 1344\u20131366 (2025).","journal-title":"Cancer Commun."},{"key":"2780_CR286","first-page":"7450","volume":"50","author":"R Andreesen","year":"1990","unstructured":"Andreesen, R. et al. Adoptive transfer of tumor cytotoxic macrophages generated in vitro from circulating blood monocytes: a new approach to cancer immunotherapy. Cancer Res. 50, 7450\u20137456 (1990).","journal-title":"Cancer Res."},{"key":"2780_CR287","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02184-8","volume":"23","author":"H Zheng","year":"2024","unstructured":"Zheng, H. et al. Chimeric antigen receptor macrophages targeting c-MET(CAR-M-c-MET) inhibit pancreatic cancer progression and improve cytotoxic chemotherapeutic efficacy. Mol. Cancer 23, 270 (2024).","journal-title":"Mol. Cancer"},{"key":"2780_CR288","doi-asserted-by":"publisher","first-page":"103873","DOI":"10.1016\/j.ebiom.2022.103873","volume":"76","author":"S Wang","year":"2022","unstructured":"Wang, S. et al. CAR-macrophage: an extensive immune enhancer to fight cancer. EBioMedicine 76, 103873 (2022).","journal-title":"EBioMedicine"},{"key":"2780_CR289","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41590-023-01687-8","volume":"25","author":"A Lei","year":"2024","unstructured":"Lei, A. et al. A second-generation M1-polarized CAR macrophage with antitumor efficacy. Nat. Immunol. 25, 102\u2013116 (2024).","journal-title":"Nat. Immunol."},{"key":"2780_CR290","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.stem.2024.04.012","volume":"31","author":"J Shen","year":"2024","unstructured":"Shen, J. et al. Activating innate immune responses repolarizes hPSC-derived CAR macrophages to improve anti-tumor activity. Cell. Stem Cell. 31, 1003\u20131019.e1009 (2024).","journal-title":"Cell. Stem Cell."},{"key":"2780_CR291","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202103258","volume":"33","author":"M Kang","year":"2021","unstructured":"Kang, M. et al. Nanocomplex-mediated in vivo programming to chimeric antigen receptor-M1 macrophages for cancer therapy. Adv. Mater. 33, e2103258 (2021).","journal-title":"Adv. Mater."},{"key":"2780_CR292","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-62506-2","volume":"16","author":"Y Xiao","year":"2025","unstructured":"Xiao, Y., Zhu, T., Chen, Z. & Huang, X. Lung metastasis and recurrence is mitigated by CAR macrophages, in-situ-generated from mRNA delivered by small extracellular vesicles. Nat. Commun. 16, 7166 (2025).","journal-title":"Nat. Commun."},{"key":"2780_CR293","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-67674-9","volume":"17","author":"K Gu","year":"2025","unstructured":"Gu, K. et al. Intraperitoneal programming of tailored CAR macrophages via mRNA lipid nanoparticle to boost cancer immunotherapy. Nat. Commun. 17, 941 (2025).","journal-title":"Nat. Commun."},{"key":"2780_CR294","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/s43018-025-00950-1","volume":"6","author":"W Jing","year":"2025","unstructured":"Jing, W. et al. An in situ engineered chimeric IL-2 receptor potentiates the tumoricidal activity of proinflammatory CAR macrophages in renal cell carcinoma. Nat. Cancer 6, 838\u2013853 (2025).","journal-title":"Nat. Cancer"},{"key":"2780_CR295","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/nri3671","volume":"14","author":"F Ginhoux","year":"2014","unstructured":"Ginhoux, F. & Jung, S. Monocytes and macrophages: developmental pathways and tissue homeostasis. Nat. Rev. Immunol. 14, 392\u2013404 (2014).","journal-title":"Nat. Rev. Immunol."},{"key":"2780_CR296","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13045-020-00983-2","volume":"13","author":"L Zhang","year":"2020","unstructured":"Zhang, L. et al. Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions. J. Hematol. Oncol. 13, 153 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"2780_CR297","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/s41591-025-03495-z","volume":"31","author":"KA Reiss","year":"2025","unstructured":"Reiss, K. A. et al. CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial. Nat. Med. 31, 1171\u20131182 (2025).","journal-title":"Nat. Med."},{"key":"2780_CR298","doi-asserted-by":"publisher","first-page":"3014","DOI":"10.1200\/JCO.2020.38.15_suppl.3014","volume":"38","author":"CM Annunziata","year":"2020","unstructured":"Annunziata, C. M. et al. Feasibility and preliminary safety and efficacy of first-in-human intraperitoneal delivery of MCY-M11, anti-human-mesothelin CAR mRNA transfected into peripheral blood mononuclear cells, for ovarian cancer and malignant peritoneal mesothelioma. J. Clin. Oncol. 38, 3014 (2020).","journal-title":"J. Clin. Oncol."},{"key":"2780_CR299","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-59326-9","volume":"16","author":"S Chen","year":"2025","unstructured":"Chen, S. et al. CAR macrophages with built-In CD47 blocker combat tumor antigen heterogeneity and activate T cells via cross-presentation. Nat. Commun. 16, 4069 (2025).","journal-title":"Nat. Commun."},{"key":"2780_CR300","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","volume":"17","author":"L Galluzzi","year":"2020","unstructured":"Galluzzi, L. et al. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat. Rev. Clin. Oncol. 17, 725\u2013741 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2780_CR301","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41392-023-01452-1","volume":"8","author":"S Chen","year":"2023","unstructured":"Chen, S. et al. Macrophages in immunoregulation and therapeutics. Signal Transduct. Target. Ther. 8, 207 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2780_CR302","doi-asserted-by":"publisher","first-page":"115587","DOI":"10.1016\/j.celrep.2025.115587","volume":"44","author":"RG Jayasinghe","year":"2025","unstructured":"Jayasinghe, R. G. et al. Single-cell transcriptomic profiling reveals diversity in human iNKT cells across hematologic tissues. Cell Rep. 44, 115587 (2025).","journal-title":"Cell Rep."},{"key":"2780_CR303","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1146\/annurev.immunol.25.022106.141711","volume":"25","author":"A Bendelac","year":"2007","unstructured":"Bendelac, A., Savage, P. B. & Teyton, L. The biology of NKT cells. Annu. Rev. Immunol. 25, 297\u2013336 (2007).","journal-title":"Annu. Rev. Immunol."},{"key":"2780_CR304","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1126\/science.278.5343.1626","volume":"278","author":"T Kawano","year":"1997","unstructured":"Kawano, T. et al. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 278, 1626\u20131629 (1997).","journal-title":"Science"},{"key":"2780_CR305","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nri3174","volume":"12","author":"E Vivier","year":"2012","unstructured":"Vivier, E. et al. Targeting natural killer cells and natural killer T cells in cancer. Nat. Rev. Immunol. 12, 239\u2013252 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"2780_CR306","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.it.2007.05.008","volume":"28","author":"M Terabe","year":"2007","unstructured":"Terabe, M. & Berzofsky, J. A. NKT cells in immunoregulation of tumor immunity: a new immunoregulatory axis. Trends Immunol. 28, 491\u2013496 (2007).","journal-title":"Trends Immunol."},{"key":"2780_CR307","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nri1309","volume":"4","author":"DI Godfrey","year":"2004","unstructured":"Godfrey, D. I. et al. NKT cells: what\u2019s in a name? Nat. Rev. Immunol. 4, 231\u2013237 (2004).","journal-title":"Nat. Rev. Immunol."},{"key":"2780_CR308","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1084\/jem.180.3.1097","volume":"180","author":"O Lantz","year":"1994","unstructured":"Lantz, O. & Bendelac, A. An invariant T cell receptor alpha chain is used by a unique subset of major histocompatibility complex class I-specific CD4+ and CD4-8- T cells in mice and humans. J. Exp. Med. 180, 1097\u20131106 (1994).","journal-title":"J. Exp. Med."},{"key":"2780_CR309","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1084\/jem.20011786","volume":"195","author":"JE Gumperz","year":"2002","unstructured":"Gumperz, J. E., Miyake, S., Yamamura, T. & Brenner, M. B. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J. Exp. Med. 195, 625\u2013636 (2002).","journal-title":"J. Exp. Med."},{"key":"2780_CR310","doi-asserted-by":"publisher","first-page":"11287","DOI":"10.1073\/pnas.0801631105","volume":"105","author":"JM Coquet","year":"2008","unstructured":"Coquet, J. M. et al. Diverse cytokine production by NKT cell subsets and identification of an IL-17-producing CD4-NK1.1- NKT cell population. Proc. Natl. Acad. Sci. USA 105, 11287\u201311292 (2008).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2780_CR311","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1084\/jem.182.4.993","volume":"182","author":"S Cardell","year":"1995","unstructured":"Cardell, S. et al. CD1-restricted CD4+ T cells in major histocompatibility complex class II-deficient mice. J. Exp. Med. 182, 993\u20131004 (1995).","journal-title":"J. Exp. Med."},{"key":"2780_CR312","doi-asserted-by":"publisher","first-page":"5637","DOI":"10.1182\/blood-2007-05-092866","volume":"111","author":"GJ Renukaradhya","year":"2008","unstructured":"Renukaradhya, G. J. et al. Type I NKT cells protect (and type II NKT cells suppress) the host\u2019s innate antitumor immune response to a B-cell lymphoma. Blood 111, 5637\u20135645 (2008).","journal-title":"Blood"},{"key":"2780_CR313","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1084\/jem.20031462","volume":"199","author":"LS Metelitsa","year":"2004","unstructured":"Metelitsa, L. S. et al. Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2. J. Exp. Med. 199, 1213\u20131221 (2004).","journal-title":"J. Exp. Med."},{"key":"2780_CR314","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1182\/blood-2016-11-751065","volume":"129","author":"F Gorini","year":"2017","unstructured":"Gorini, F. et al. Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis. Blood 129, 3440\u20133451 (2017).","journal-title":"Blood"},{"key":"2780_CR315","doi-asserted-by":"publisher","first-page":"648917","DOI":"10.3389\/fimmu.2021.648917","volume":"12","author":"R Tang","year":"2021","unstructured":"Tang, R. et al. Deciphering the prognostic implications of the components and signatures in the immune microenvironment of pancreatic ductal adenocarcinoma. Front. Immunol. 12, 648917 (2021).","journal-title":"Front. Immunol."},{"key":"2780_CR316","doi-asserted-by":"publisher","first-page":"7322","DOI":"10.1158\/1078-0432.CCR-05-0877","volume":"11","author":"T Tachibana","year":"2005","unstructured":"Tachibana, T. et al. Increased intratumor Valpha24-positive natural killer T cells: a prognostic factor for primary colorectal carcinomas. Clin. Cancer Res. 11, 7322\u20137327 (2005).","journal-title":"Clin. Cancer Res."},{"key":"2780_CR317","first-page":"5102","volume":"59","author":"T Kawano","year":"1999","unstructured":"Kawano, T. et al. Antitumor cytotoxicity mediated by ligand-activated human V alpha24 NKT cells. Cancer Res. 59, 5102\u20135105 (1999).","journal-title":"Cancer Res."},{"key":"2780_CR318","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1002\/eji.200940278","volume":"41","author":"C Kuylenstierna","year":"2011","unstructured":"Kuylenstierna, C. et al. NKG2D performs two functions in invariant NKT cells: direct TCR-independent activation of NK-like cytolysis and co-stimulation of activation by CD1d. Eur. J. Immunol. 41, 1913\u20131923 (2011).","journal-title":"Eur. J. Immunol."},{"key":"2780_CR319","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1084\/jem.20030324","volume":"198","author":"S Fujii","year":"2003","unstructured":"Fujii, S. et al. Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J. Exp. Med. 198, 267\u2013279 (2003).","journal-title":"J. Exp. Med."},{"key":"2780_CR320","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1182\/blood-2005-10-4184","volume":"108","author":"DH Chang","year":"2006","unstructured":"Chang, D. H. et al. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 108, 618\u2013621 (2006).","journal-title":"Blood"},{"key":"2780_CR321","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1172\/JCI37869","volume":"119","author":"L Song","year":"2009","unstructured":"Song, L. et al. Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. J. Clin. Invest. 119, 1524\u20131536 (2009).","journal-title":"J. Clin. Invest."},{"key":"2780_CR322","doi-asserted-by":"publisher","first-page":"4036","DOI":"10.1172\/JCI36264","volume":"118","author":"C De Santo","year":"2008","unstructured":"De Santo, C. et al. Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans. J. Clin. Invest. 118, 4036\u20134048 (2008).","journal-title":"J. Clin. Invest."},{"key":"2780_CR323","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/ni827","volume":"3","author":"S Fujii","year":"2002","unstructured":"Fujii, S., Shimizu, K., Kronenberg, M. & Steinman, R. M. Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs. Nat. Immunol. 3, 867\u2013874 (2002).","journal-title":"Nat. Immunol."},{"key":"2780_CR324","doi-asserted-by":"publisher","first-page":"570","DOI":"10.3389\/fimmu.2017.00570","volume":"8","author":"CW Keller","year":"2017","unstructured":"Keller, C. W., Freigang, S. & L\u00fcnemann, J. D. Reciprocal crosstalk between dendritic cells and natural killer T cells: mechanisms and therapeutic potential. Front. Immunol. 8, 570 (2017).","journal-title":"Front. Immunol."},{"key":"2780_CR325","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1158\/1078-0432.CCR-04-1453","volume":"11","author":"A Ishikawa","year":"2005","unstructured":"Ishikawa, A. et al. A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin. Cancer Res. 11, 1910\u20131917 (2005).","journal-title":"Clin. Cancer Res."},{"key":"2780_CR326","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000316","volume":"8","author":"T Toyoda","year":"2020","unstructured":"Toyoda, T. et al. Phase II study of \u03b1-galactosylceramide-pulsed antigen-presenting cells in patients with advanced or recurrent non-small cell lung cancer. J. Immunother. Cancer 8, e000316 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"2780_CR327","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1111\/j.1349-7006.2009.01135.x","volume":"100","author":"N Kunii","year":"2009","unstructured":"Kunii, N. et al. Combination therapy of in vitro-expanded natural killer T cells and \u03b1-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma. Cancer Sci. 100, 1092\u20131098 (2009).","journal-title":"Cancer Sci."},{"key":"2780_CR328","doi-asserted-by":"publisher","first-page":"3510","DOI":"10.1158\/1078-0432.CCR-16-0600","volume":"23","author":"MA Exley","year":"2017","unstructured":"Exley, M. A. et al. Adoptive transfer of invariant NKT cells as immunotherapy for advanced melanoma: a phase I clinical trial. Clin. Cancer Res. 23, 3510\u20133519 (2017).","journal-title":"Clin. Cancer Res."},{"key":"2780_CR329","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.2217\/fon-2017-0724","volume":"14","author":"Q Xu","year":"2018","unstructured":"Xu, Q. et al. Utilization of invariant natural killer T cells for gastric cancer treatment. Future Oncol. 14, 2053\u20132066 (2018).","journal-title":"Future Oncol."},{"key":"2780_CR330","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/s41388-024-02948-y","volume":"43","author":"MJ Hadfield","year":"2024","unstructured":"Hadfield, M. J. et al. Overcoming resistance to programmed cell death protein 1 (PD-1) blockade with allogeneic invariant natural killer T-cells (iNKT). Oncogene 43, 758\u2013762 (2024).","journal-title":"Oncogene"},{"key":"2780_CR331","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1182\/blood-2013-11-541235","volume":"124","author":"A Heczey","year":"2014","unstructured":"Heczey, A. et al. Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy. Blood 124, 2824\u20132833 (2014).","journal-title":"Blood"},{"key":"2780_CR332","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1038\/s43018-024-00830-0","volume":"5","author":"X Zhou","year":"2024","unstructured":"Zhou, X. et al. CAR-redirected natural killer T cells demonstrate superior antitumor activity to CAR-T cells through multimodal CD1d-dependent mechanisms. Nat. Cancer 5, 1607\u20131621 (2024).","journal-title":"Nat. Cancer"},{"key":"2780_CR333","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s41232-023-00275-5","volume":"43","author":"T Aoki","year":"2023","unstructured":"Aoki, T., Motohashi, S. & Koseki, H. Regeneration of invariant natural killer T (iNKT) cells: application of iPSC technology for iNKT cell-targeted tumor immunotherapy. Inflamm. Regen. 43, 27 (2023).","journal-title":"Inflamm. Regen."},{"key":"2780_CR334","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.ccell.2018.08.017","volume":"34","author":"A Rotolo","year":"2018","unstructured":"Rotolo, A. et al. Enhanced anti-lymphoma activity of CAR19-iNKT cells underpinned by dual CD19 and CD1d targeting. Cancer Cell 34, 596\u2013610.e511 (2018).","journal-title":"Cancer Cell"},{"key":"2780_CR335","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.stem.2019.08.004","volume":"25","author":"Y Zhu","year":"2019","unstructured":"Zhu, Y. et al. Development of hematopoietic stem cell-engineered invariant natural killer T cell therapy for cancer. Cell. Stem Cell. 25, 542\u2013557.e549 (2019).","journal-title":"Cell. Stem Cell."},{"key":"2780_CR336","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/j.ymthe.2024.04.005","volume":"32","author":"YR Li","year":"2024","unstructured":"Li, Y. R. et al. Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapy. Mol. Ther. 32, 1849\u20131874 (2024).","journal-title":"Mol. Ther."},{"key":"2780_CR337","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41587-024-02226-y","volume":"43","author":"YR Li","year":"2025","unstructured":"Li, Y. R. et al. Generation of allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture method. Nat. Biotechnol. 43, 329\u2013344 (2025).","journal-title":"Nat. Biotechnol."},{"key":"2780_CR338","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1038\/s41591-020-1074-2","volume":"26","author":"A Heczey","year":"2020","unstructured":"Heczey, A. et al. Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis. Nat. Med. 26, 1686\u20131690 (2020).","journal-title":"Nat. Med."},{"key":"2780_CR339","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13045-025-01736-9","volume":"18","author":"YR Li","year":"2025","unstructured":"Li, Y. R. et al. Targeting triple-negative breast cancer using cord-blood CD34\u207a HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity. J. Hematol. Oncol. 18, 86 (2025).","journal-title":"J. Hematol. Oncol."},{"key":"2780_CR340","doi-asserted-by":"publisher","first-page":"102321","DOI":"10.1016\/j.xcrm.2025.102321","volume":"6","author":"YR Li","year":"2025","unstructured":"Li, Y. R. et al. Multimodal targeting of metastatic renal cell carcinoma via CD70-directed allogeneic CAR-NKT cells. Cell Rep. Med. 6, 102321 (2025).","journal-title":"Cell Rep. Med."},{"key":"2780_CR341","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56270-6","volume":"16","author":"Y-R Li","year":"2025","unstructured":"Li, Y.-R. et al. Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies. Nat. Commun. 16, 1248 (2025).","journal-title":"Nat. Commun."},{"key":"2780_CR342","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14332-x","volume":"11","author":"S Fu","year":"2020","unstructured":"Fu, S. et al. Impaired lipid biosynthesis hinders anti-tumor efficacy of intratumoral iNKT cells. Nat. Commun. 11, 438 (2020).","journal-title":"Nat. Commun."},{"key":"2780_CR343","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1428156","volume":"7","author":"\u00c9 Dockry","year":"2018","unstructured":"Dockry, \u00c9 et al. Epigenetic induction of CD1d expression primes lung cancer cells for killing by invariant natural killer T cells. Oncoimmunology 7, e1428156 (2018).","journal-title":"Oncoimmunology"},{"key":"2780_CR344","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.actbio.2018.06.029","volume":"76","author":"V Sainz","year":"2018","unstructured":"Sainz, V. et al. \u03b1-Galactosylceramide and peptide-based nano-vaccine synergistically induced a strong tumor suppressive effect in melanoma. Acta Biomater. 76, 193\u2013207 (2018).","journal-title":"Acta Biomater."},{"key":"2780_CR345","doi-asserted-by":"publisher","first-page":"e00232-20","DOI":"10.1128\/CMR.00232-20","volume":"34","author":"NMS G\u00e1lvez","year":"2021","unstructured":"G\u00e1lvez, N. M. S. et al. Type I natural killer T cells as key regulators of the immune response to infectious diseases. Clin. Microbiol. Rev. 34, e00232-20 (2021).","journal-title":"Clin. Microbiol. Rev."},{"key":"2780_CR346","first-page":"994","volume":"118","author":"K Stirnemann","year":"2008","unstructured":"Stirnemann, K. et al. Sustained activation and tumor targeting of NKT cells using a CD1d-anti-HER2-scFv fusion protein induce antitumor effects in mice. J. Clin. Invest. 118, 994\u20131005 (2008).","journal-title":"J. Clin. Invest."},{"key":"2780_CR347","doi-asserted-by":"publisher","DOI":"10.21769\/BioProtoc.2277","volume":"7","author":"D Yamada","year":"2017","unstructured":"Yamada, D. et al. Efficient production of functional human NKT cells from induced pluripotent stem cells - reprogramming of human V\u03b124(+)iNKT cells. Bio Protoc. 7, e2277 (2017).","journal-title":"Bio Protoc."},{"key":"2780_CR348","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002096","volume":"9","author":"S Gebremeskel","year":"2021","unstructured":"Gebremeskel, S. et al. Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis. J. Immunother. Cancer 9, e002096 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"2780_CR349","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20202077","volume":"218","author":"GJ Randolph","year":"2021","unstructured":"Randolph, G. J. Dendritic cells: the first step. J. Exp. Med. 218, e20202077 (2021).","journal-title":"J. Exp. Med."},{"key":"2780_CR350","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1146\/annurev-immunol-061020-053707","volume":"39","author":"M Cabeza-Cabrerizo","year":"2021","unstructured":"Cabeza-Cabrerizo, M. et al. Dendritic cells revisited. Annu. Rev. Immunol. 39, 131\u2013166 (2021).","journal-title":"Annu. Rev. Immunol."},{"key":"2780_CR351","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41571-024-00859-1","volume":"21","author":"I Heras-Murillo","year":"2024","unstructured":"Heras-Murillo, I. et al. Dendritic cells as orchestrators of anticancer immunity and immunotherapy. Nat. Rev. Clin. Oncol. 21, 257\u2013277 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2780_CR352","doi-asserted-by":"publisher","first-page":"102412","DOI":"10.1016\/j.xcrm.2025.102412","volume":"6","author":"G Clayton","year":"2025","unstructured":"Clayton, G., Toffoli, E. C., de Gruijl, T. D. & van Kooyk, Y. Dendritic cell immunotherapy advances for solid tumors: vaccination and modulation. Cell Rep. Med. 6, 102412 (2025).","journal-title":"Cell Rep. Med."},{"key":"2780_CR353","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13045-020-00939-6","volume":"13","author":"Y Wang","year":"2020","unstructured":"Wang, Y. et al. Dendritic cell biology and its role in tumor immunotherapy. J. Hematol. Oncol. 13, 107 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"2780_CR354","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","volume":"20","author":"SK Wculek","year":"2020","unstructured":"Wculek, S. K. et al. Dendritic cells in cancer immunology and immunotherapy. Nat. Rev. Immunol. 20, 7\u201324 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"2780_CR355","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1146\/annurev-immunol-032414-112334","volume":"33","author":"J Rossjohn","year":"2015","unstructured":"Rossjohn, J. et al. T cell antigen receptor recognition of antigen-presenting molecules. Annu. Rev. Immunol. 33, 169\u2013200 (2015).","journal-title":"Annu. Rev. Immunol."},{"key":"2780_CR356","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaz7548","volume":"368","author":"Z Zhou","year":"2020","unstructured":"Zhou, Z. et al. Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells. Science 368, eaaz7548 (2020).","journal-title":"Science"},{"key":"2780_CR357","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/ni.3294","volume":"17","author":"TY Halim","year":"2016","unstructured":"Halim, T. Y. et al. Group 2 innate lymphoid cells license dendritic cells to potentiate memory TH2 cell responses. Nat. Immunol. 17, 57\u201364 (2016).","journal-title":"Nat. Immunol."},{"key":"2780_CR358","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1084\/jem.137.5.1142","volume":"137","author":"RM Steinman","year":"1973","unstructured":"Steinman, R. M. & Cohn, Z. A. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J. Exp. Med. 137, 1142\u20131162 (1973).","journal-title":"J. Exp. Med."},{"key":"2780_CR359","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/32588","volume":"392","author":"J Banchereau","year":"1998","unstructured":"Banchereau, J. & Steinman, R. M. Dendritic cells and the control of immunity. Nature 392, 245\u2013252 (1998).","journal-title":"Nature"},{"key":"2780_CR360","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff, P. W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411\u2013422 (2010).","journal-title":"N. Engl. J. Med."},{"key":"2780_CR361","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1182\/bloodadvances.2017014175","volume":"2","author":"PG Maslak","year":"2018","unstructured":"Maslak, P. G. et al. Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia. Blood Adv. 2, 224\u2013234 (2018).","journal-title":"Blood Adv."},{"key":"2780_CR362","doi-asserted-by":"publisher","first-page":"7483","DOI":"10.1158\/1078-0432.CCR-17-2169","volume":"23","author":"MG Zauderer","year":"2017","unstructured":"Zauderer, M. G. et al. A randomized phase II trial of adjuvant galinpepimut-S, WT-1 analogue peptide vaccine, after multimodality therapy for patients with malignant pleural mesothelioma. Clin. Cancer Res. 23, 7483\u20137489 (2017).","journal-title":"Clin. Cancer Res."},{"key":"2780_CR363","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45358-0","volume":"15","author":"KF Bol","year":"2024","unstructured":"Bol, K. F. et al. Adjuvant dendritic cell therapy in stage IIIB\/C melanoma: the MIND-DC randomized phase III trial. Nat. Commun. 15, 1632 (2024).","journal-title":"Nat. Commun."},{"key":"2780_CR364","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1001\/jamaoncol.2022.5370","volume":"9","author":"LM Liau","year":"2023","unstructured":"Liau, L. M. et al. Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a phase 3 prospective externally controlled cohort trial. JAMA Oncol. 9, 112\u2013121 (2023).","journal-title":"JAMA Oncol."},{"key":"2780_CR365","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009765","volume":"12","author":"S Koido","year":"2024","unstructured":"Koido, S. et al. Dendritic cells pulsed with multifunctional Wilms\u2019 tumor 1 (WT1) peptides combined with multiagent chemotherapy modulate the tumor microenvironment and enable conversion surgery in pancreatic cancer. J. Immunother. Cancer 12, e009765 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"2780_CR366","doi-asserted-by":"publisher","first-page":"4108","DOI":"10.1158\/1538-7445.AM2024-4108","volume":"84","author":"Y Chen","year":"2024","unstructured":"Chen, Y. et al. Safety and feasibility of personalized neoantigen DC vaccines in postoperative esophagus squamous cell carcinoma: a Phase 1b trial. Cancer Res. 84, 4108 (2024).","journal-title":"Cancer Res."},{"key":"2780_CR367","first-page":"6952","volume":"62","author":"C-LS Lin","year":"2002","unstructured":"Lin, C.-L. S. et al. Immunization with Epstein-Barr Virus (EBV) peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma. Cancer Res. 62, 6952\u20136958 (2002).","journal-title":"Cancer Res."},{"key":"2780_CR368","doi-asserted-by":"publisher","first-page":"620374","DOI":"10.3389\/fimmu.2020.620374","volume":"11","author":"D Stevens","year":"2020","unstructured":"Stevens, D. et al. Dendritic cell-based immunotherapy in lung cancer. Front. Immunol. 11, 620374 (2020).","journal-title":"Front. Immunol."},{"key":"2780_CR369","doi-asserted-by":"publisher","DOI":"10.1126\/science.adn9083","volume":"386","author":"E Ascic","year":"2024","unstructured":"Ascic, E. et al. In vivo dendritic cell reprogramming for cancer immunotherapy. Science 386, eadn9083 (2024).","journal-title":"Science"},{"key":"2780_CR370","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41551-025-01343-6","volume":"9","author":"J Wang","year":"2025","unstructured":"Wang, J. et al. Targeting vaccines to dendritic cells by mimicking the processing and presentation of antigens in xenotransplant rejection. Nat. Biomed. Eng. 9, 201\u2013214 (2025).","journal-title":"Nat. Biomed. Eng."},{"key":"2780_CR371","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202403663","volume":"11","author":"J Kim","year":"2024","unstructured":"Kim, J. et al. Dual adjuvant-loaded peptide antigen self-assembly potentiates dendritic cell-mediated tumor immunotherapy. Adv. Sci. 11, e2403663 (2024).","journal-title":"Adv. Sci."},{"key":"2780_CR372","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202311574","volume":"36","author":"S Qi","year":"2024","unstructured":"Qi, S. et al. Supramolecular lipid nanoparticles based on host-guest recognition: a new generation delivery system of mRNA vaccines for cancer immunotherapy. Adv. Mater. 36, e2311574 (2024).","journal-title":"Adv. Mater."},{"key":"2780_CR373","doi-asserted-by":"publisher","first-page":"38267","DOI":"10.1021\/acsnano.5c09365","volume":"19","author":"C Zhang","year":"2025","unstructured":"Zhang, C. et al. mRNA-based vaccination drives in vivo dendritic cell reprogramming and selective cytotoxic T lymphocyte modulation for enhanced antitumor immunity. ACS Nano. 19, 38267\u201338283 (2025).","journal-title":"ACS Nano."},{"key":"2780_CR374","doi-asserted-by":"publisher","first-page":"101229","DOI":"10.1016\/j.xcrm.2023.101229","volume":"4","author":"J Dan","year":"2023","unstructured":"Dan, J. et al. Oncolytic virus M1 functions as a bifunctional checkpoint inhibitor to enhance the antitumor activity of DC vaccine. Cell Rep. Med. 4, 101229 (2023).","journal-title":"Cell Rep. Med."},{"key":"2780_CR375","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202301096","volume":"12","author":"N Falcone","year":"2023","unstructured":"Falcone, N. et al. Peptide hydrogels as immunomaterials and their use in cancer immunotherapy delivery. Adv. Health. Mater. 12, e2301096 (2023).","journal-title":"Adv. Health. Mater."},{"key":"2780_CR376","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202301339","volume":"10","author":"H Dong","year":"2023","unstructured":"Dong, H. et al. Biomaterials facilitating dendritic cell-mediated cancer immunotherapy. Adv. Sci. 10, e2301339 (2023).","journal-title":"Adv. Sci."},{"key":"2780_CR377","first-page":"29","volume":"17","author":"X Han","year":"2022","unstructured":"Han, X. et al. Biomaterial-assisted biotherapy: a brief review of biomaterials used in drug delivery, vaccine development, gene therapy, and stem cell therapy. Bioact. Mater. 17, 29\u201348 (2022).","journal-title":"Bioact. Mater."},{"key":"2780_CR378","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s41568-022-00466-1","volume":"22","author":"CM Laumont","year":"2022","unstructured":"Laumont, C. M. et al. Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities. Nat. Rev. Cancer 22, 414\u2013430 (2022).","journal-title":"Nat. Rev. Cancer"},{"key":"2780_CR379","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.ccell.2023.02.017","volume":"41","author":"CM Laumont","year":"2023","unstructured":"Laumont, C. M. & Nelson, B. H. B cells in the tumor microenvironment: multi-faceted organizers, regulators, and effectors of anti-tumor immunity. Cancer Cell 41, 466\u2013489 (2023).","journal-title":"Cancer Cell"},{"key":"2780_CR380","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/s41591-018-0057-z","volume":"24","author":"DS Thommen","year":"2018","unstructured":"Thommen, D. S. et al. A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nat. Med. 24, 994\u20131004 (2018).","journal-title":"Nat. Med."},{"key":"2780_CR381","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.ccell.2021.09.007","volume":"39","author":"V Engelhard","year":"2021","unstructured":"Engelhard, V. et al. B cells and cancer. Cancer Cell 39, 1293\u20131296 (2021).","journal-title":"Cancer Cell"},{"key":"2780_CR382","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","volume":"19","author":"C Saut\u00e8s-Fridman","year":"2019","unstructured":"Saut\u00e8s-Fridman, C., Petitprez, F., Calderaro, J. & Fridman, W. H. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat. Rev. Cancer 19, 307\u2013325 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"2780_CR383","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1053\/j.gastro.2023.10.022","volume":"166","author":"C Hu","year":"2024","unstructured":"Hu, C. et al. Tertiary lymphoid structure-associated B cells enhance CXCL13(+)CD103(+)CD8(+) tissue-resident memory T-cell response to programmed cell death protein 1 blockade in cancer immunotherapy. Gastroenterology 166, 1069\u20131084 (2024).","journal-title":"Gastroenterology"},{"key":"2780_CR384","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001136","volume":"9","author":"M Yang","year":"2021","unstructured":"Yang, M. et al. CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer. J. Immunother. Cancer 9, e001136 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"2780_CR385","doi-asserted-by":"publisher","DOI":"10.1126\/science.adj4857","volume":"384","author":"J Ma","year":"2024","unstructured":"Ma, J. et al. A blueprint for tumor-infiltrating B cells across human cancers. Science 384, eadj4857 (2024).","journal-title":"Science"},{"key":"2780_CR386","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-020-02064-6","volume":"21","author":"J Chen","year":"2020","unstructured":"Chen, J. et al. Single-cell transcriptome and antigen-immunoglobin analysis reveals the diversity of B cells in non-small cell lung cancer. Genome Biol. 21, 152 (2020).","journal-title":"Genome Biol."},{"key":"2780_CR387","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1158\/2326-6066.CIR-20-0949","volume":"9","author":"K Wennhold","year":"2021","unstructured":"Wennhold, K. et al. CD86(+) antigen-presenting B cells are increased in cancer, localize in tertiary lymphoid structures, and induce specific T-cell responses. Cancer Immunol. Res. 9, 1098\u20131108 (2021).","journal-title":"Cancer Immunol. Res."},{"key":"2780_CR388","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05606-9","volume":"22","author":"X Cai","year":"2024","unstructured":"Cai, X. et al. Re-analysis of single cell and spatial transcriptomics data reveals B cell landscape in gastric cancer microenvironment and its potential crosstalk with tumor cells for clinical prognosis. J. Transl. Med. 22, 807 (2024).","journal-title":"J. Transl. Med."},{"key":"2780_CR389","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.immuni.2022.02.001","volume":"55","author":"M Meylan","year":"2022","unstructured":"Meylan, M. et al. Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer. Immunity 55, 527\u2013541.e525 (2022).","journal-title":"Immunity"},{"key":"2780_CR390","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/s41586-020-03144-0","volume":"591","author":"S Biswas","year":"2021","unstructured":"Biswas, S. et al. IgA transcytosis and antigen recognition govern ovarian cancer immunity. Nature 591, 464\u2013470 (2021).","journal-title":"Nature"},{"key":"2780_CR391","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.cell.2023.12.015","volume":"187","author":"Z Li","year":"2024","unstructured":"Li, Z. et al. Therapeutic application of human type 2 innate lymphoid cells via induction of granzyme B-mediated tumor cell death. Cell 187, 624\u2013641.e623 (2024).","journal-title":"Cell"},{"key":"2780_CR392","doi-asserted-by":"publisher","first-page":"6125","DOI":"10.1158\/1078-0432.CCR-18-1481","volume":"24","author":"MCA Wouters","year":"2018","unstructured":"Wouters, M. C. A. & Nelson, B. H. Prognostic significance of tumor-infiltrating B cells and plasma cells in human cancer. Clin. Cancer Res. 24, 6125\u20136135 (2018).","journal-title":"Clin. Cancer Res."},{"key":"2780_CR393","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/s40425-019-0726-6","volume":"7","author":"K Hlad\u00edkov\u00e1","year":"2019","unstructured":"Hlad\u00edkov\u00e1, K. et al. Tumor-infiltrating B cells affect the progression of oropharyngeal squamous cell carcinoma via cell-to-cell interactions with CD8(+) T cells. J. Immunother. Cancer 7, 261 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"2780_CR394","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","volume":"577","author":"R Cabrita","year":"2020","unstructured":"Cabrita, R. et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature 577, 561\u2013565 (2020).","journal-title":"Nature"},{"key":"2780_CR395","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","volume":"577","author":"F Petitprez","year":"2020","unstructured":"Petitprez, F. et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature 577, 556\u2013560 (2020).","journal-title":"Nature"},{"key":"2780_CR396","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","volume":"577","author":"BA Helmink","year":"2020","unstructured":"Helmink, B. A. et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577, 549\u2013555 (2020).","journal-title":"Nature"},{"key":"2780_CR397","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1097\/JTO.0b013e3182217bec","volume":"6","author":"EB Gottlin","year":"2011","unstructured":"Gottlin, E. B. et al. The Association of Intratumoral Germinal Centers with early-stage non-small cell lung cancer. J. Thorac. Oncol. 6, 1687\u20131690 (2011).","journal-title":"J. Thorac. Oncol."},{"key":"2780_CR398","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1016\/j.ccell.2025.07.001","volume":"43","author":"AC Cole","year":"2025","unstructured":"Cole, A. C. et al. Adoptively transferred Th17 cells cooperate with host B cells to achieve durable tumor immunity. Cancer Cell 43, 1697\u20131713.e1698 (2025).","journal-title":"Cancer Cell"},{"key":"2780_CR399","doi-asserted-by":"publisher","first-page":"111295","DOI":"10.1016\/j.celrep.2022.111295","volume":"40","author":"Y Xu","year":"2022","unstructured":"Xu, Y. et al. Tumor-infiltrated activated B cells suppress liver metastasis of colorectal cancers. Cell Rep. 40, 111295 (2022).","journal-title":"Cell Rep."},{"key":"2780_CR400","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1164\/rccm.201010-1738OC","volume":"183","author":"R Sorrentino","year":"2011","unstructured":"Sorrentino, R. et al. B cells contribute to the antitumor activity of CpG-oligodeoxynucleotide in a mouse model of metastatic lung carcinoma. Am. J. Respir. Crit. Care Med. 183, 1369\u20131379 (2011).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2780_CR401","doi-asserted-by":"publisher","first-page":"4987","DOI":"10.1158\/1078-0432.CCR-11-0207","volume":"17","author":"Q Li","year":"2011","unstructured":"Li, Q. et al. Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regression. Clin. Cancer Res. 17, 4987\u20134995 (2011).","journal-title":"Clin. Cancer Res."},{"key":"2780_CR402","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/j.cell.2019.10.028","volume":"179","author":"DP Hollern","year":"2019","unstructured":"Hollern, D. P. et al. B cells and T follicular helper cells mediate response to checkpoint inhibitors in high mutation burden mouse models of breast cancer. Cell 179, 1191\u20131206.e1121 (2019).","journal-title":"Cell"},{"key":"2780_CR403","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1002\/ijc.34438","volume":"152","author":"A Jo","year":"2023","unstructured":"Jo, A. et al. CTLA-4 inhibition facilitates follicular T and B cell interaction and the production of tumor-specific antibodies. Int. J. Cancer 152, 1964\u20131976 (2023).","journal-title":"Int. J. Cancer"},{"key":"2780_CR404","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1038\/s43018-022-00447-1","volume":"3","author":"I Yofe","year":"2022","unstructured":"Yofe, I. et al. Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through Fc\u03b3R engagement and type I interferon signaling. Nat. Cancer 3, 1336\u20131350 (2022).","journal-title":"Nat. Cancer"},{"key":"2780_CR405","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1038\/s41591-020-1085-z","volume":"26","author":"N van Dijk","year":"2020","unstructured":"van Dijk, N. et al. Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. Nat. Med. 26, 1839\u20131844 (2020).","journal-title":"Nat. Med."},{"key":"2780_CR406","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins, F. et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat. Rev. Clin. Oncol. 16, 563\u2013580 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2780_CR407","doi-asserted-by":"publisher","first-page":"221ra213","DOI":"10.1126\/scitranslmed.3007323","volume":"6","author":"L Maldonado","year":"2014","unstructured":"Maldonado, L. et al. Intramuscular therapeutic vaccination targeting HPV16 induces T cell responses that localize in mucosal lesions. Sci. Transl. Med. 6, 221ra213 (2014).","journal-title":"Sci. Transl. Med."},{"key":"2780_CR408","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn, R. S. et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 382, 1894\u20131905 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2780_CR409","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","volume":"393","author":"BI Rini","year":"2019","unstructured":"Rini, B. I. et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet 393, 2404\u20132415 (2019).","journal-title":"Lancet"},{"key":"2780_CR410","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1322238","volume":"6","author":"AM Weinstein","year":"2017","unstructured":"Weinstein, A. M. et al. Tbet and IL-36\u03b3 cooperate in therapeutic DC-mediated promotion of ectopic lymphoid organogenesis in the tumor microenvironment. Oncoimmunology 6, e1322238 (2017).","journal-title":"Oncoimmunology"},{"key":"2780_CR411","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.immuni.2004.09.006","volume":"21","author":"T Cupedo","year":"2004","unstructured":"Cupedo, T., Jansen, W., Kraal, G. & Mebius, R. E. Induction of secondary and tertiary lymphoid structures in the skin. Immunity 21, 655\u2013667 (2004).","journal-title":"Immunity"},{"key":"2780_CR412","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1038\/nbt1039","volume":"22","author":"S Suematsu","year":"2004","unstructured":"Suematsu, S. & Watanabe, T. Generation of a synthetic lymphoid tissue\u2013like organoid in mice. Nat. Biotechnol. 22, 1539\u20131545 (2004).","journal-title":"Nat. Biotechnol."},{"key":"2780_CR413","doi-asserted-by":"publisher","first-page":"4556","DOI":"10.1158\/1078-0432.CCR-16-2821","volume":"23","author":"JM Lee","year":"2017","unstructured":"Lee, J. M. et al. Phase I trial of intratumoral injection of CCL21 gene-modified dendritic cells in lung cancer elicits tumor-specific immune responses and CD8(+) T-cell infiltration. Clin. Cancer Res. 23, 4556\u20134568 (2017).","journal-title":"Clin. Cancer Res."},{"key":"2780_CR414","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/eji.201646568","volume":"47","author":"M Mathieu","year":"2017","unstructured":"Mathieu, M. et al. Inflammation enhances the vaccination potential of CD40-activated B cells in mice. Eur. J. Immunol. 47, 269\u2013279 (2017).","journal-title":"Eur. J. Immunol."},{"key":"2780_CR415","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200913","volume":"218","author":"C Lee-Chang","year":"2021","unstructured":"Lee-Chang, C. et al. Activation of 4-1BBL+ B cells with CD40 agonism and IFN\u03b3 elicits potent immunity against glioblastoma. J. Exp. Med. 218, e20200913 (2021).","journal-title":"J. Exp. Med."},{"key":"2780_CR416","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1182\/blood-2014-04-569061","volume":"124","author":"G Romain","year":"2014","unstructured":"Romain, G. et al. Antibody Fc engineering improves frequency and promotes kinetic boosting of serial killing mediated by NK cells. Blood 124, 3241\u20133249 (2014).","journal-title":"Blood"},{"key":"2780_CR417","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1158\/0008-5472.CAN-12-4184","volume":"73","author":"M Bodogai","year":"2013","unstructured":"Bodogai, M. et al. Anti-CD20 antibody promotes cancer escape via enrichment of tumor-evoked regulatory B cells expressing low levels of CD20 and CD137L. Cancer Res. 73, 2127\u20132138 (2013).","journal-title":"Cancer Res."},{"key":"2780_CR418","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00452-4","volume":"8","author":"R Somasundaram","year":"2017","unstructured":"Somasundaram, R. et al. Tumor-associated B-cells induce tumor heterogeneity and therapy resistance. Nat. Commun. 8, 607 (2017).","journal-title":"Nat. Commun."},{"key":"2780_CR419","doi-asserted-by":"publisher","first-page":"3316","DOI":"10.1038\/s41388-018-0668-3","volume":"38","author":"S Das","year":"2019","unstructured":"Das, S. & Bar-Sagi, D. BTK signaling drives CD1d(hi)CD5(+) regulatory B-cell differentiation to promote pancreatic carcinogenesis. Oncogene 38, 3316\u20133324 (2019).","journal-title":"Oncogene"},{"key":"2780_CR420","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1158\/2159-8290.CD-15-0827","volume":"6","author":"AJ Gunderson","year":"2016","unstructured":"Gunderson, A. J. et al. Bruton tyrosine kinase-dependent immune cell cross-talk drives pancreas cancer. Cancer Discov. 6, 270\u2013285 (2016).","journal-title":"Cancer Discov."},{"key":"2780_CR421","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s41586-022-05254-3","volume":"610","author":"S Li","year":"2022","unstructured":"Li, S. et al. STING-induced regulatory B cells compromise NK function in cancer immunity. Nature 610, 373\u2013380 (2022).","journal-title":"Nature"},{"key":"2780_CR422","doi-asserted-by":"publisher","first-page":"100744","DOI":"10.1016\/j.xcrm.2022.100744","volume":"3","author":"B Mirlekar","year":"2022","unstructured":"Mirlekar, B. et al. Balance between immunoregulatory B cells and plasma cells drives pancreatic tumor immunity. Cell Rep. Med. 3, 100744 (2022).","journal-title":"Cell Rep. Med."},{"key":"2780_CR423","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/s41392-022-01134-4","volume":"7","author":"DM Hoang","year":"2022","unstructured":"Hoang, D. M. et al. Stem cell-based therapy for human diseases. Signal Transduct. Target. Ther. 7, 272 (2022).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2780_CR424","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1146\/annurev-biochem-013118-111829","volume":"88","author":"S Ma","year":"2019","unstructured":"Ma, S., Meng, Z., Chen, R. & Guan, K. L. The Hippo pathway: biology and pathophysiology. Annu. Rev. Biochem. 88, 577\u2013604 (2019).","journal-title":"Annu. Rev. Biochem."},{"key":"2780_CR425","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.immuni.2006.10.016","volume":"25","author":"T Sugiyama","year":"2006","unstructured":"Sugiyama, T., Kohara, H., Noda, M. & Nagasawa, T. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 25, 977\u2013988 (2006).","journal-title":"Immunity"},{"key":"2780_CR426","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.cytogfr.2018.06.002","volume":"43","author":"V de Ara\u00fajo Farias","year":"2018","unstructured":"de Ara\u00fajo Farias, V., Carrillo-G\u00e1lvez, A. B., Mart\u00edn, F. & Anderson, P. TGF-\u03b2 and mesenchymal stromal cells in regenerative medicine, autoimmunity and cancer. Cytokine Growth Factor Rev. 43, 25\u201337 (2018).","journal-title":"Cytokine Growth Factor Rev."},{"key":"2780_CR427","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s40164-025-00688-7","volume":"14","author":"L Sun","year":"2025","unstructured":"Sun, L. et al. Tumor-associated mesenchymal stem\/stromal cells in tumor microenvironment and carcinogenesis. Exp. Hematol. Oncol. 14, 97 (2025).","journal-title":"Exp. Hematol. Oncol."},{"key":"2780_CR428","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.matbio.2013.10.003","volume":"34","author":"TP Lozito","year":"2014","unstructured":"Lozito, T. P., Jackson, W. M., Nesti, L. J. & Tuan, R. S. Human mesenchymal stem cells generate a distinct pericellular zone of MMP activities via binding of MMPs and secretion of high levels of TIMPs. Matrix Biol. 34, 132\u2013143 (2014).","journal-title":"Matrix Biol."},{"key":"2780_CR429","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41551-024-01309-0","volume":"9","author":"N Li","year":"2025","unstructured":"Li, N. et al. Potent prophylactic cancer vaccines harnessing surface antigens shared by tumour cells and induced pluripotent stem cells. Nat. Biomed. Eng. 9, 215\u2013233 (2025).","journal-title":"Nat. Biomed. Eng."},{"key":"2780_CR430","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.stem.2007.05.013","volume":"1","author":"M Ramalho-Santos","year":"2007","unstructured":"Ramalho-Santos, M. & Willenbring, H. On the origin of the term \u201cstem cell\u201d. Cell. Stem Cell. 1, 35\u201338 (2007).","journal-title":"Cell. Stem Cell."},{"key":"2780_CR431","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.tmrv.2005.02.006","volume":"19","author":"J Jansen","year":"2005","unstructured":"Jansen, J. The first successful allogeneic bone-marrow transplant: Georges Math\u00e9. Transfus. Med Rev. 19, 246\u2013248 (2005).","journal-title":"Transfus. Med Rev."},{"key":"2780_CR432","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41551-018-0325-8","volume":"3","author":"JQ Yin","year":"2019","unstructured":"Yin, J. Q., Zhu, J. & Ankrum, J. A. Manufacturing of primed mesenchymal stromal cells for therapy. Nat. Biomed. Eng. 3, 90\u2013104 (2019).","journal-title":"Nat. Biomed. Eng."},{"key":"2780_CR433","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1001\/jamaoncol.2023.5757","volume":"10","author":"R Huang","year":"2024","unstructured":"Huang, R. et al. Mesenchymal stem cells for prophylaxis of chronic graft-vs-host disease after haploidentical hematopoietic stem cell transplant: an open-label randomized clinical trial. JAMA Oncol. 10, 220\u2013226 (2024).","journal-title":"JAMA Oncol."},{"key":"2780_CR434","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1200\/JCO-24-02119","volume":"43","author":"H Yao","year":"2025","unstructured":"Yao, H. et al. Sequential infusion of mesenchymal stem cell for graft-versus-host disease prevention in haploidentical hematopoietic stem cell transplantation: an open-label, multicenter, randomized controlled clinical trial. J. Clin. Oncol. 43, 1997\u20132006 (2025).","journal-title":"J. Clin. Oncol."},{"key":"2780_CR435","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41423-020-0429-4","volume":"18","author":"C Lv","year":"2021","unstructured":"Lv, C. et al. Pluripotent stem cell-derived CD19-CAR iT cells effectively eradicate B-cell lymphoma in vivo. Cell Mol. Immunol. 18, 773\u2013775 (2021).","journal-title":"Cell Mol. Immunol."},{"key":"2780_CR436","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13425","volume":"56","author":"C Wang","year":"2023","unstructured":"Wang, C., Liu, J. & Li, W. \u2018Off the shelf\u2019 immunotherapies: Generation and application of pluripotent stem cell-derived immune cells. Cell Prolif. 56, e13425 (2023).","journal-title":"Cell Prolif."},{"key":"2780_CR437","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1182\/blood.V122.21.900.900","volume":"122","author":"R Gardner","year":"2013","unstructured":"Gardner, R. et al. Lentiviral transduction of Notch ligand expanded cord blood HSC\u2019s to express a CD19-specific CAR generates NK and myeloid progeny with antitumor activity. Blood 122, 900 (2013).","journal-title":"Blood"},{"key":"2780_CR438","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.jconrel.2024.09.037","volume":"375","author":"H Zhang","year":"2024","unstructured":"Zhang, H. et al. New avenues for cancer immunotherapy: cell-mediated drug delivery systems. J. Control Release 375, 712\u2013732 (2024).","journal-title":"J. Control Release"},{"key":"2780_CR439","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-07443-0","volume":"16","author":"Y Shi","year":"2025","unstructured":"Shi, Y. et al. Engineered mesenchymal stem\/stromal cells against cancer. Cell Death Dis. 16, 113 (2025).","journal-title":"Cell Death Dis."},{"key":"2780_CR440","doi-asserted-by":"publisher","first-page":"101685","DOI":"10.1016\/j.xcrm.2024.101685","volume":"5","author":"G Grisendi","year":"2024","unstructured":"Grisendi, G. et al. Combining gemcitabine and MSC delivering soluble TRAIL to target pancreatic adenocarcinoma and its stroma. Cell Rep. Med. 5, 101685 (2024).","journal-title":"Cell Rep. Med."},{"key":"2780_CR441","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-022-01012-0","volume":"21","author":"N Ghasemi Darestani","year":"2023","unstructured":"Ghasemi Darestani, N. et al. Mesenchymal stem cell-released oncolytic virus: an innovative strategy for cancer treatment. Cell Commun. Signal. 21, 43 (2023).","journal-title":"Cell Commun. Signal."},{"key":"2780_CR442","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-35935-0","volume":"14","author":"YH Lai","year":"2023","unstructured":"Lai, Y. H. et al. Stem cell-nanomedicine system as a theranostic bio-gadolinium agent for targeted neutron capture cancer therapy. Nat. Commun. 14, 285 (2023).","journal-title":"Nat. Commun."},{"key":"2780_CR443","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1158\/1535-7163.MCT-17-0682","volume":"17","author":"B Layek","year":"2018","unstructured":"Layek, B., Sadhukha, T., Panyam, J. & Prabha, S. Nano-engineered mesenchymal stem cells increase therapeutic efficacy of anticancer drug through true active tumor targeting. Mol. Cancer Ther. 17, 1196\u20131206 (2018).","journal-title":"Mol. Cancer Ther."},{"key":"2780_CR444","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13045-025-01746-7","volume":"18","author":"Y Chen","year":"2025","unstructured":"Chen, Y. et al. Recent advances in CAR-MSCs: the new engine of cellular immunotherapy evolution. J. Hematol. Oncol. 18, 92 (2025).","journal-title":"J. Hematol. Oncol."},{"key":"2780_CR445","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/s41551-024-01195-6","volume":"8","author":"O Sirpilla","year":"2024","unstructured":"Sirpilla, O. et al. Mesenchymal stromal cells with chimaeric antigen receptors for enhanced immunosuppression. Nat. Biomed. Eng. 8, 443\u2013460 (2024).","journal-title":"Nat. Biomed. Eng."},{"key":"2780_CR446","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01191-4","volume":"21","author":"L Yan","year":"2023","unstructured":"Yan, L., Li, J. & Zhang, C. The role of MSCs and CAR-MSCs in cellular immunotherapy. Cell Commun. Signal. 21, 187 (2023).","journal-title":"Cell Commun. Signal."},{"key":"2780_CR447","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1182\/blood-2022-158872","volume":"140","author":"O Sirpilla","year":"2022","unstructured":"Sirpilla, O. et al. Chimeric antigen receptor engineering of mesenchymal stromal cells (CAR-MSC) enhance immunosuppression and outcomes in graft versus host disease (GvHD) preclinical models. Blood 140, 1579\u20131580 (2022).","journal-title":"Blood"},{"key":"2780_CR448","doi-asserted-by":"publisher","first-page":"1385571","DOI":"10.3389\/fimmu.2024.1385571","volume":"15","author":"Z Niu","year":"2024","unstructured":"Niu, Z. et al. CAR-based immunotherapy for breast cancer: peculiarities, ongoing investigations, and future strategies. Front. Immunol. 15, 1385571 (2024).","journal-title":"Front. Immunol."},{"key":"2780_CR449","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41417-018-0062-x","volume":"27","author":"G Golinelli","year":"2020","unstructured":"Golinelli, G. et al. Targeting GD2-positive glioblastoma by chimeric antigen receptor empowered mesenchymal progenitors. Cancer Gene Ther. 27, 558\u2013570 (2020).","journal-title":"Cancer Gene Ther."},{"key":"2780_CR450","doi-asserted-by":"publisher","first-page":"101240","DOI":"10.1016\/j.tranon.2021.101240","volume":"15","author":"G Golinelli","year":"2022","unstructured":"Golinelli, G. et al. Anti-GD2 CAR MSCs against metastatic Ewing\u2019s sarcoma. Transl. Oncol. 15, 101240 (2022).","journal-title":"Transl. Oncol."},{"key":"2780_CR451","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.73","volume":"5","author":"R Aliperta","year":"2015","unstructured":"Aliperta, R. et al. Bispecific antibody releasing-mesenchymal stromal cell machinery for retargeting T cells towards acute myeloid leukemia blasts. Blood Cancer J. 5, e348 (2015).","journal-title":"Blood Cancer J."},{"key":"2780_CR452","doi-asserted-by":"publisher","first-page":"112343","DOI":"10.1016\/j.isci.2025.112343","volume":"28","author":"S Tang","year":"2025","unstructured":"Tang, S. et al. NKG2D-CAR-targeted iPSC-derived MSCs efficiently target solid tumors expressing NKG2D ligand. iScience 28, 112343 (2025).","journal-title":"iScience"},{"key":"2780_CR453","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.stem.2025.03.004","volume":"32","author":"T Deuse","year":"2025","unstructured":"Deuse, T. & Schrepfer, S. Progress and challenges in developing allogeneic cell therapies. Cell. Stem Cell. 32, 513\u2013528 (2025).","journal-title":"Cell. Stem Cell."},{"key":"2780_CR454","doi-asserted-by":"publisher","first-page":"127ps9","DOI":"10.1126\/scitranslmed.3003920","volume":"4","author":"SJ Sharkis","year":"2012","unstructured":"Sharkis, S. J., Jones, R. J., Civin, C. & Jang, Y. Y. Pluripotent stem cell-based cancer therapy: promise and challenges. Sci. Transl. Med. 4, 127ps9 (2012).","journal-title":"Sci. Transl. Med."},{"key":"2780_CR455","doi-asserted-by":"publisher","first-page":"30720","DOI":"10.1021\/acsnano.5c02321","volume":"19","author":"Z Zhang","year":"2025","unstructured":"Zhang, Z. et al. Advances in nanomedicine for targeting cancer stem cells and overcoming therapeutic resistance. ACS Nano. 19, 30720\u201330757 (2025).","journal-title":"ACS Nano."},{"key":"2780_CR456","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","volume":"21","author":"JN Brudno","year":"2024","unstructured":"Brudno, J. N. & Kochenderfer, J. N. Current understanding and management of CAR T cell-associated toxicities. Nat. Rev. Clin. Oncol. 21, 501\u2013521 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2780_CR457","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13045-024-01579-w","volume":"17","author":"P Sesques","year":"2024","unstructured":"Sesques, P. et al. Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma. J. Hematol. Oncol. 17, 61 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"2780_CR458","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1016\/j.ymthe.2024.11.035","volume":"33","author":"YR Li","year":"2025","unstructured":"Li, Y. R. et al. Managing allorejection in off-the-shelf CAR-engineered cell therapies. Mol. Ther. 33, 2368\u20132390 (2025).","journal-title":"Mol. Ther."},{"key":"2780_CR459","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq, S., Hackett, C. S. & Brentjens, R. J. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat. Rev. Clin. Oncol. 17, 147\u2013167 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2780_CR460","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41573-024-01100-5","volume":"24","author":"A Mulvey","year":"2025","unstructured":"Mulvey, A., Trueb, L., Coukos, G. & Arber, C. Novel strategies to manage CAR-T cell toxicity. Nat. Rev. Drug Discov. 24, 379\u2013397 (2025).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2780_CR461","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.chembiol.2023.10.024","volume":"31","author":"IC Lane","year":"2024","unstructured":"Lane, I. C. et al. Genetic retargeting of E3 ligases to enhance CAR T cell therapy. Cell Chem. Biol. 31, 338\u2013348.e335 (2024).","journal-title":"Cell Chem. Biol."},{"key":"2780_CR462","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/s41570-025-00768-6","volume":"9","author":"EL Adams","year":"2025","unstructured":"Adams, E. L. et al. Small-molecule control of CAR T cells. Nat. Rev. Chem. 9, 809\u2013825 (2025).","journal-title":"Nat. Rev. Chem."},{"key":"2780_CR463","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aay9209","volume":"6","author":"Z Huang","year":"2020","unstructured":"Huang, Z. et al. Engineering light-controllable CAR T cells for cancer immunotherapy. Sci. Adv. 6, eaay9209 (2020).","journal-title":"Sci. Adv."},{"key":"2780_CR464","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb6295","volume":"13","author":"M Jan","year":"2021","unstructured":"Jan, M. et al. Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide. Sci. Transl. Med. 13, eabb6295 (2021).","journal-title":"Sci. Transl. Med."},{"key":"2780_CR465","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1038\/s41551-023-01084-4","volume":"7","author":"X Li","year":"2023","unstructured":"Li, X. et al. Suppression of cytokine release syndrome during CAR-T-cell therapy via a subcutaneously injected interleukin-6-adsorbing hydrogel. Nat. Biomed. Eng. 7, 1129\u20131141 (2023).","journal-title":"Nat. Biomed. Eng."},{"key":"2780_CR466","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.1182\/blood-2016-01-628982","volume":"127","author":"CM Bollard","year":"2016","unstructured":"Bollard, C. M. & Heslop, H. E. T cells for viral infections after allogeneic hematopoietic stem cell transplant. Blood 127, 3331\u20133340 (2016).","journal-title":"Blood"},{"key":"2780_CR467","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/j.ajt.2024.05.019","volume":"24","author":"L Schweitzer","year":"2024","unstructured":"Schweitzer, L. & Muranski, P. Virus-specific T cell therapy to treat refractory viral infections in solid organ transplant recipients. Am. J. Transplant. 24, 1558\u20131566 (2024).","journal-title":"Am. J. Transplant."},{"key":"2780_CR468","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202205902","volume":"61","author":"R Tang","year":"2022","unstructured":"Tang, R. et al. A chimeric conjugate of antibody and programmable DNA nanoassembly smartly activates T cells for precise cancer cell targeting. Angew. Chem. Int. Ed. Engl. 61, e202205902 (2022).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"2780_CR469","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ccell.2019.02.003","volume":"35","author":"S Srivastava","year":"2019","unstructured":"Srivastava, S. et al. Logic-gated ROR1 chimeric antigen receptor expression rescues T cell-mediated toxicity to normal tissues and enables selective tumor targeting. Cancer Cell 35, 489\u2013503.e488 (2019).","journal-title":"Cancer Cell"},{"key":"2780_CR470","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1038\/s41590-023-01659-y","volume":"24","author":"OK Dagher","year":"2023","unstructured":"Dagher, O. K. & Posey, A. D. Jr Forks in the road for CAR T and CAR NK cell cancer therapies. Nat. Immunol. 24, 1994\u20132007 (2023).","journal-title":"Nat. Immunol."},{"key":"2780_CR471","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/s41577-021-00539-6","volume":"21","author":"JD Chan","year":"2021","unstructured":"Chan, J. D. et al. Cellular networks controlling T cell persistence in adoptive cell therapy. Nat. Rev. Immunol. 21, 769\u2013784 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"2780_CR472","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aba6884","volume":"6","author":"O Levy","year":"2020","unstructured":"Levy, O. et al. Shattering barriers toward clinically meaningful MSC therapies. Sci. Adv. 6, eaba6884 (2020).","journal-title":"Sci. Adv."},{"key":"2780_CR473","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.bbmt.2014.05.004","volume":"20","author":"JS Miller","year":"2014","unstructured":"Miller, J. S. et al. Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration: implications for clinical therapy. Biol. Blood Marrow Transplant. 20, 1252\u20131257 (2014).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"2780_CR474","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/cr.2016.157","volume":"27","author":"RL Sabado","year":"2017","unstructured":"Sabado, R. L., Balan, S. & Bhardwaj, N. Dendritic cell-based immunotherapy. Cell Res. 27, 74\u201395 (2017).","journal-title":"Cell Res."},{"key":"2780_CR475","doi-asserted-by":"publisher","first-page":"6317","DOI":"10.1016\/j.cell.2025.07.046","volume":"188","author":"Z Wu","year":"2025","unstructured":"Wu, Z. et al. Glycan shielding enables TCR-sufficient allogeneic CAR-T therapy. Cell 188, 6317\u20136334.e6321 (2025).","journal-title":"Cell"},{"key":"2780_CR476","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaz6579","volume":"6","author":"CWT Shields","year":"2020","unstructured":"Shields, C. W. T. et al. Cellular backpacks for macrophage immunotherapy. Sci. Adv. 6, eaaz6579 (2020).","journal-title":"Sci. Adv."},{"key":"2780_CR477","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s41586-025-09518-6","volume":"647","author":"S Li","year":"2025","unstructured":"Li, S. et al. Amplifying antigen-induced cellular responses with proximity labelling. Nature 647, 506\u2013516 (2025).","journal-title":"Nature"},{"key":"2780_CR478","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-024-01625-7","volume":"17","author":"K Ai","year":"2024","unstructured":"Ai, K. et al. Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies. J. Hematol. Oncol. 17, 105 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"2780_CR479","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.ccell.2025.03.019","volume":"43","author":"B Du","year":"2025","unstructured":"Du, B. et al. CAR-T therapy in solid tumors. Cancer Cell 43, 665\u2013679 (2025).","journal-title":"Cancer Cell"},{"key":"2780_CR480","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41392-024-02096-5","volume":"10","author":"P Wang","year":"2025","unstructured":"Wang, P. et al. Chimeric antigen receptor with novel intracellular modules improves antitumor performance of T cells. Signal Transduct. Target. Ther. 10, 20 (2025).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2780_CR481","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007162","volume":"11","author":"S Papa","year":"2023","unstructured":"Papa, S. et al. Intratumoral pan-ErbB targeted CAR-T for head and neck squamous cell carcinoma: interim analysis of the T4 immunotherapy study. J. Immunother. Cancer 11, e007162 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"2780_CR482","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/s41591-024-03451-3","volume":"31","author":"NA Vitanza","year":"2025","unstructured":"Vitanza, N. A. et al. Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial. Nat. Med. 31, 861\u2013868 (2025).","journal-title":"Nat. Med."},{"key":"2780_CR483","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1158\/1078-0432.CCR-12-1879","volume":"19","author":"EH Aarntzen","year":"2013","unstructured":"Aarntzen, E. H. et al. Targeting of 111In-labeled dendritic cell human vaccines improved by reducing number of cells. Clin. Cancer Res. 19, 1525\u20131533 (2013).","journal-title":"Clin. Cancer Res."},{"key":"2780_CR484","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1182\/blood.2025029584","volume":"146","author":"Z DeFilipp","year":"2025","unstructured":"DeFilipp, Z. et al. RGI-2001 for the prophylaxis of acute graft-versus-host disease after allogeneic HCT. Blood 146, 2037\u20132046 (2025).","journal-title":"Blood"},{"key":"2780_CR485","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.trsl.2025.08.002","volume":"283","author":"M He","year":"2025","unstructured":"He, M. et al. Noninvasive in vivo tracking of SPIONs-labeled CLDN18.2-targeted CAR-T cells in gastric cancer via magnetic particle imaging. Transl. Res. 283, 3\u201312 (2025).","journal-title":"Transl. Res."},{"key":"2780_CR486","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jconrel.2022.03.021","volume":"345","author":"JQ Liu","year":"2022","unstructured":"Liu, J. Q. et al. Intratumoral delivery of IL-12 and IL-27 mRNA using lipid nanoparticles for cancer immunotherapy. J. Control Release 345, 306\u2013313 (2022).","journal-title":"J. Control Release"},{"key":"2780_CR487","doi-asserted-by":"publisher","first-page":"102518","DOI":"10.1016\/j.nantod.2024.102518","volume":"59","author":"Y Li","year":"2024","unstructured":"Li, Y. et al. In situ engineering of mRNA-CAR T cells using spleen-targeted ionizable lipid nanoparticles to eliminate cancer cells. Nano Today 59, 102518 (2024).","journal-title":"Nano Today"},{"key":"2780_CR488","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil, S. et al. \u2018Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges. Nat. Rev. Drug Discov. 19, 185\u2013199 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2780_CR489","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/nrd.2017.266","volume":"17","author":"A Yip","year":"2018","unstructured":"Yip, A. & Webster, R. M. The market for chimeric antigen receptor T cell therapies. Nat. Rev. Drug Discov. 17, 161\u2013162 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2780_CR490","doi-asserted-by":"publisher","first-page":"904","DOI":"10.2106\/JBJS.18.00915","volume":"101","author":"IR Murray","year":"2019","unstructured":"Murray, I. R. et al. International expert consensus on a cell therapy communication tool: DOSES. J. Bone Jt. Surg. Am. 101, 904\u2013911 (2019).","journal-title":"J. Bone Jt. Surg. Am."},{"key":"2780_CR491","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s44178-026-00235-2","volume":"5","author":"X Liu","year":"2026","unstructured":"Liu, X., Kuang, L., Wu, L. & Li, Y. High throughput sequencing in oncology: from tumor characterization to novel therapies. Holist. Integr. Oncol. 5, 16 (2026).","journal-title":"Holist. Integr. Oncol."},{"key":"2780_CR492","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/s41568-024-00706-6","volume":"24","author":"R Polak","year":"2024","unstructured":"Polak, R., Zhang, E. T. & Kuo, C. J. Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment. Nat. Rev. Cancer 24, 523\u2013539 (2024).","journal-title":"Nat. Rev. Cancer"},{"key":"2780_CR493","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.ymthe.2017.03.010","volume":"25","author":"C Zhang","year":"2017","unstructured":"Zhang, C. et al. Phase I escalating-dose trial of CAR-T therapy targeting CEA(+) metastatic colorectal cancers. Mol. Ther. 25, 1248\u20131258 (2017).","journal-title":"Mol. Ther."},{"key":"2780_CR494","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1007\/s00432-021-03613-7","volume":"147","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y. et al. Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggyBac transposon system in advanced relapsed\/refractory non-small cell lung cancer patients. J. Cancer Res. Clin. Oncol. 147, 3725\u20133734 (2021).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"2780_CR495","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1001\/jamaoncol.2017.0184","volume":"3","author":"N Ahmed","year":"2017","unstructured":"Ahmed, N. et al. HER2-specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial. JAMA Oncol. 3, 1094\u20131101 (2017).","journal-title":"JAMA Oncol."},{"key":"2780_CR496","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","volume":"387","author":"MW Rohaan","year":"2022","unstructured":"Rohaan, M. W. et al. Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma. N. Engl. J. Med. 387, 2113\u20132125 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2780_CR497","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/s41591-021-01462-y","volume":"27","author":"BC Creelan","year":"2021","unstructured":"Creelan, B. C. et al. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. Nat. Med. 27, 1410\u20131418 (2021).","journal-title":"Nat. Med."},{"key":"2780_CR498","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1200\/JCO.21.00612","volume":"39","author":"AA Sarnaik","year":"2021","unstructured":"Sarnaik, A. A. et al. Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma. J. Clin. Oncol. 39, 2656\u20132666 (2021).","journal-title":"J. Clin. Oncol."},{"key":"2780_CR499","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/s41591-023-02363-y","volume":"29","author":"A Heczey","year":"2023","unstructured":"Heczey, A. et al. Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results. Nat. Med. 29, 1379\u20131388 (2023).","journal-title":"Nat. Med."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02780-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02780-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02780-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T23:02:26Z","timestamp":1782860546000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02780-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":499,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2780"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02780-8","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"23 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"255"}}